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Abstract
Background: Systematic reviews should provide trustworthy guidance to decision-makers, but their credibility is
challenged by the selective reporting of trial results and outcomes. Some trials are not published, and even among
clinical trials that are published partially (e.g., as conference abstracts), many are never published in full. Although
there are many potential sources of published and unpublished data for systematic reviews, there are no established
methods for choosing among multiple reports or data sources about the same trial.
Methods: We will conduct systematic reviews of the effectiveness and safety of two interventions following the
Institute of Medicine (IOM) guidelines: (1) gabapentin for neuropathic pain and (2) quetiapine for bipolar depression.
For the review of gabapentin, we will include adult participants with neuropathic pain who do not require ventilator
support. For the review of quetiapine, we will include adult participants with acute bipolar depression (excluding
mixed or rapid cycling episodes). We will compare these drugs (used alone or in combination with other interventions)
with placebo or with the same intervention alone; direct comparisons with other medications will be excluded. For
each review, we will conduct highly sensitive electronic searches, and the results of the searches will be assessed by
two independent reviewers. Outcomes, study characteristics, and risk of bias ratings will be extracted from multiple
reports by two individuals working independently, stored in a publicly available database (Systematic Review Data
Repository) and analyzed using commonly available statistical software. In each review, we will conduct a series of
meta-analyses using data from different sources to determine how the results are affected by the inclusion of data
from multiple published sources (e.g., journal articles and conference abstracts) as well as unpublished aggregate data
(e.g., “clinical study reports”) and individual participant data (IPD). We will identify patient-centered outcomes in each
report and identify differences in the reporting of these outcomes across sources.
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Background
Multiple sources of data
Systematic reviews and meta-analyses are comparative
effectiveness research methods that involve summarizing
existing research to establish how well treatments work.
Systematic reviews should provide trustworthy guidance
to decision-makers, but their credibility is challenged by
the selective reporting of trial results and outcomes.
Some trials are not published, and even among clinical
trials that are published partially (e.g., as conference
abstracts), many are never published in full [1].
Failure to publish is not random. Studies favoring the
comparator or null findings are less likely to be pub-
lished compared with studies that favor the test treat-
ment, known as publication bias [2]. Even when studies
are published, authors may report selectively the statis-
tically significant outcomes favoring the test treatment;
they may not publish outcomes favoring the compara-
tor or outcomes for which there were no statistical dif-
ferences observed between treatments. This is known
as selective outcome reporting bias [3]. Additionally,
analyses of reported trials are often not done on an
“intention to treat” basis, in which all randomized
patients are analyzed as part of the group to which they
were assigned, leaving such results vulnerable to selec-
tion bias despite randomization [4]. Readers may esti-
mate results for dichotomous outcomes with missing
cases by assuming that participants did or did not
improve, and systematic reviewers can conduct sensi-
tivity analyses to explore how continuous variables are
affected by post-randomization exclusions, but the val-
idity of the assumptions underlying these methods may
be difficult to test.
Failure to report research is a tremendous waste [5].
In addition, and of arguably more importance, treatment
decisions on the basis of biased reporting may harm
people by the prescription of treatments that are less
effective and more harmful than what the systematic
reviews suggest. Thus, to decrease the threat of report-
ing biases, current best practices for the conduct of sys-
tematic reviews include searching for unpublished trial
results as well as the “grey” literature such as conference
abstracts [6].
There are many potential sources of published and
unpublished data, and there are no established methods
for choosing among multiple reports or data sources
about the same trial. Moreover, most reports such as
journal publications and trial registries include only data
summaries at the group level (i.e., aggregate data), and
other reports (e.g., conference abstracts, posters, and
regulatory packets submitted for approval) may include
only fragmentary and incomplete study details. Some
sources, such as conference abstracts, may be so select-
ively reported that their inclusion in a meta-analysis
could increase rather than reduce bias [7]; however,
supplementing short reports with additional informa-
tion from trial registries could provide a more complete
account of trials when longer reports are unavailable
[8]. Individual participant data (IPD), by contrast, may
include more details than reports of aggregate results,
and IPD can be re-analyzed when patient data have
been omitted from published analyses. However, IPD
are rarely available for all included studies in systematic
reviews.
A few studies have examined possible methods for
supplementing information from published reports. For
example, studies have compared the reliability of meta-
analytic estimates in systematic reviews using data sub-
mitted to the Food and Drug Administration (FDA) and
published data [9]. There are numerous cases in which
unpublished trials have come to light and summary data
from those studies have been used in systematic reviews
about clinical efficacy, but these cases typically pick a
perceived “best” source for each meta-analysis and do
not show how meta-analyses would be affected by the
inclusion of data from different sources [10–12]. These
studies show that when information is present from
multiple sources, it does not always agree, and there are
no guidelines for choosing which data to include in a
systematic review under these circumstances.
IPD are generally considered the best data for perform-
ing traditional meta-analysis, not aggregate (summary)
data [13]. While authors have noted that “individual par-
ticipant data are not needed if all the required aggregate
data can be obtained in full,” the reality is that reviewers
rarely know when this is the case [14]. In addition, analyz-
ing IPD without detailed attention to other elements of
study design (such as details about data collection) can
lead to superficial and erroneous interpretations of re-
sults. One study compared differences between meta-
analyses using published data and meta-analyses using IPD
[12, 15], and a second meta-analysis using the same data
noted that internal correspondence and other documents
about the trials would bring further insight [11], suggesting
that even more data sources might be useful in systematic
reviews that already include individual participant data.
Given the potential for meta-bias [3], it seems obvious
that reviewers should search for and include all relevant
and reliable data in systematic reviews. On the other
hand, comprehensive searching adds to the time and re-
sources required to complete systematic reviews. Despite
the potential value of individual-level data, at this time,
it is unclear if the results of systematic reviews using
IPD necessarily differ substantively from reviews based
on reports of aggregate data. Thus, it is not known if the
additional resources required for identifying, obtaining,
and analyzing each type of unpublished data are worth-
while. Empirically grounded guidance is needed to guide
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reviewer choices about the use of data from multiple
sources.
Patient-centered outcomes
Patient-centered outcomes research helps people “commu-
nicate and make informed healthcare decisions” (http://
www.pcori.org/assets/March-5-Definition-of-PCOR11.pdf),
yet many clinical trials and systematic reviews do not fulfill
these goals. A primary reason for this deficiency is a histor-
ical lack of attention to the selection of patient-centered
outcomes for analysis. This project seeks to identify
patient-centered outcomes for two systematic reviews using
a combination of methods that other reviewers could repli-
cate to improve the patient-centeredness of their research.
Across systematic reviews of a topic, there is a ten-
dency to focus on questions that are answerable and to
report outcomes that are available in published reports.
This happens even when systematic review authors
would prefer to focus on outcomes they consider im-
portant but which do not appear in publication. When
this kind of availability bias occurs, results published in
reports of clinical trials and, thus in systematic reviews,
may not be the most meaningful outcomes for people
with health problems.
Randomized trials are often expensive (largely because
of the effort involved in ensuring high-quality data col-
lection and follow-up), and trialists typically collect more
data than they can report in journal publications. If
searching for unpublished reports results in the identifi-
cation of patient-centered outcomes that were recorded
but not included in trial publications, then these efforts
might improve the quality and utility of systematic
reviews by aiding the inclusion of patient-centered out-
comes. As far as we are aware, this possibility has never
been addressed. Examining such data sources for patient-
centered outcomes could reduce the need for additional
studies and improve the efficiency of patient-centered out-
comes research.
Similarly, reports of clinical trials and systematic reviews
typically focus on one time point (e.g., the end of treat-
ment or longest follow-up). From a patient’s perspective,
these time points may or may not relate to the natural
course or treatment of their problem.
Objectives
Our objective is to explore the reliability, validity, and
utility of incorporating data from multiple data sources.
We will assess the impact of using various data sources
on effect estimates for efficacy and harms, and on clin-
ical inference, in two high-impact case studies.
To examine the sensitivity of conclusions to the data
sources used, we will conduct sequential meta-analyses in
which we systematically replace data from less complete
sources (e.g., conference abstracts) with data from more
complete sources (e.g., journal articles and internal com-
pany documents) and with IPD for two systematic
reviews. We will evaluate the validity of meta-analyses
using these sources by comparing (1) the risk of bias for
each analysis and (2) the average effects of meta-analyses
based on these sources. We will describe the utility of
using additional data sources in meta-analyses, including
the information gained by including short reports (e.g.,
conferences abstracts) and unpublished data (e.g., internal
company reports and IPD) in addition to journal articles.
We will examine the reliability of sources by comparing
outcomes and effects across multiple reports of trials.
Methods
Selection of case studies
To evaluate the effect of using data from multiple sources
in systematic reviews, we will conduct reviews of the
effectiveness and safety of (1) gabapentin (Neurontin®) for
neuropathic pain in adults and (2) quetiapine (Seroquel®)
for the treatment of depression in adults with bipolar dis-
order. We will use similar methods for both reviews, as
described in this section. The specific inclusion and exclu-
sion criteria will reflect the important clinical issues in
each area and are described in the sections that follow.
Both reviews will be conducted according to IOM stan-
dards [16]. These reviews will be used as case studies to
explore the use of multiple data sources.
These cases were selected for several reasons. Firstly,
gabapentin and quetiapine are used commonly for these
respective conditions, so the included studies will be
clinically important. Secondly, pain and depression are
associated with several patient-reported outcomes. Self-
reported outcomes related to patient perception share
common features and complexities in their measure-
ment, so methodological guidance from this project will
be relevant to other areas of patient-centered research.
Trials in such areas also commonly record outcomes
that are not patient-centered [17], and we aim to identify
the extent to which the outcomes in multiple data
sources are patient-centered. Methodologically, these
cases will also allow us to consider different situations
that systematic reviewers might face with respect to data
from multiple sources.
Gabapentin was initially approved for the treatment of
epilepsy. At the time the medication was developed, it
was not common to register clinical trials prospectively.
Furthermore, much of the use of gabapentin for neuro-
pathic pain has been off-label for indications not
approved by FDA, and data about the use of gabapentin
for these indications were not submitted to regulators to
our knowledge. Although we do not expect to find that
many trials of gabapentin for neuropathic pain were
publicly registered, there is evidence of selective outcomes
reporting and publication bias in trials of gabapentin for
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neuropathic pain [18]. Multiple data sources are available
for several trials as a consequence of litigation for which
one of the authors (KD) was an expert witness. A list of
trials conducted by the developer, internal company docu-
ments (Inferential Analysis Plans, Research Reports, and
memos) and databases containing individual patient data
were provided by Pfizer to the plaintiffs’ lawyers without
codebooks, and these were then given to KD to assist with
her testimony.
By comparison, quetiapine was initially approved for
the treatment of psychotic disorders and later ap-
proved for the treatment of bipolar disorder. Several
trials of quetiapine for bipolar disorder were registered
prospectively. Although the drug is used off-label, the
prescription of quetiapine for bipolar disorder has
been largely on-label (i.e., this indication was approved
by FDA). There is also evidence of publication bias
among trials of antipsychotics including quetiapine
[19]. These cases thus represent two different and im-
portant situations that reviewers might encounter with
different types of medications and access to multiple
data sources.
Types of studies
We will include randomized controlled trials. We will
exclude N-of-1 trials, observational studies, quasi-
randomized controlled trials (e.g., alternating allocation),
and non-randomized studies. We will exclude studies in
which providers or participants were aware of group
assignment (i.e., open-label studies). Studies will be con-
sidered for inclusion regardless of publication status or
language of publication.
Current guidelines suggest that parallel group and cross-
over studies can be combined for analysis if the crossover
design is appropriate for the condition and intervention
under investigation [11], though poor reporting often
limits their inclusion in meta-analysis [20, 21]. For this
review, we will identify crossover studies, but we will not
include them in the meta-analysis. Neuropathic pain is
relatively stable and likely to return in the absence of
effective therapy, but short-term crossover studies may
have limited clinical relevance for a chronic condition.
Bipolar depression is an unstable condition and antipsy-
chotics are not well tolerated, so withdrawals from the
first period of a study could make a second period unin-
terpretable. Crossover studies that are otherwise eligible
will be described in the excluded studies.
We will analyze studies enrolling people who are not
taking the study drug prior to the start of the trial (i.e.,
we will include only studies of people initiating treat-
ment with gabapentin or quetiapine). Discontinuation
studies will be described but not analyzed. The rationale
for this decision is that the efficacy and safety of medica-
tions may differ for studies randomizing (1) people who
are treatment naïve and (2) people who have responded
to a study drug. For example, discontinuation studies
may enroll people already taking the study drug and ran-
domly assign them to continue taking it or switch to pla-
cebo, thus excluding people who do not respond to the
treatment and people who experience adverse events
and discontinue treatment.
Comparison interventions
Studies will be included if gabapentin or quetiapine is
the only intervention that varies between treatment
groups. That is, we will include studies of each medica-
tion in combination with other therapies compared with
the other therapies alone. In factorial studies making
more than one eligible comparison (e.g., A versus B and
AC versus BC), we will treat these as separate compari-
sons (rather than combine intervention and control
groups within trials).
Comparisons of different doses or formulations of the
same drug, comparisons with other treatments, and dis-
continuation studies will not be analyzed for this report.
Identifying patient-centered outcomes
In the funding application for this study, we described
plans to select outcomes and time points in collabor-
ation with patient and stakeholder partners. As planned,
we created a list of symptoms and outcomes that matter
most to patients taking gabapentin for neuropathic pain
and to patients taking quetiapine for bipolar depression.
We identified patient-centered outcomes to be examined
using the following methods:
1. We examined the website “PatientsLikeMe” (http://
www.patientslikeme.com/), which is a website to
identify and record patient-identified outcomes
reported by patients. PatientsLikeMe allows people
to enter information about their medical history and
interventions they have used. People can describe
their experience with interventions, including
effectiveness and adverse effects. We did not use
the information on effectiveness because it is
reported in a format that includes the percentage of
people who rated the subjective effectiveness in
different categories (e.g., very effective, not effective
at all) without clearly defining outcomes in a way
that would allow us to compare this information
with the results from the trials. Information about
adverse- effects is reported as the six most commonly
rated effects in a report for each medication, which
we will identify and include in our reviews.
2. We examined the compendium “DRUGDEX”
(http://micromedex.com/), which is used by health
care providers to make treatment decisions.
DRUGDEX is a commercial website. The Centers
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for Medicare and Medicaid (CMS) may use
DRUGDEX ratings to make reimbursement
decisions related to medically accepted, FDA
unapproved anti-cancer treatment regimens.
DRUGDEX contains a list of each drug’s adverse
effects by organ system.
3. For pain outcomes, we reviewed the Initiative on
Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) consensus
recommendations [22]. The mission of IMMPACT
is to develop consensus reviews and
recommendations for improving the design,
execution, and interpretation of clinical trials of
treatments for pain (http://www.immpact.org/).
The IMMPACT group includes researchers,
manufacturers, and people with chronic pain.
4. We used PubMed, patient websites, PCORI-funded
projects, and the James Lind Alliance to identify
additional outcomes.
5. Patient and stakeholder partners identified outcomes
they thought should be included in each review.
We discussed the outcomes identified through all
sources and selected those that patient and stakeholder
partners thought were most patient-centered. The out-
comes for each review are included in the sections that
follow.
Identifying patient-centered time points
Working with patients and clinicians, we also identified
time points that are important in these conditions.
Neuropathic pain and bipolar disorder are both chronic
conditions, and patients with these conditions have indi-
cated that long-term outcomes are more meaningful
than short-term outcomes. However, acute treatment is
related to long-term management in both cases, so
investigators might reasonably focus on either short- or
long-term results. For people with bipolar disorder,
interventions that are effective for an acute episode may
be used prophylactically over longer periods of time.
Most studies about bipolar disorder are designed to
measure recovery from an episode rather than the
long-term prevention of relapses. Because a drug that
is ineffective during an acute episode would not typic-
ally be continued, long-term studies often randomize
people to continue taking a drug or to discontinue a
drug to which they responded during an episode of
mania or depression. For people with chronic pain, it
may be impossible to predict who will respond to a
given treatment, so people often try a drug for a short
period and continue treatment if it is associated with
symptom relief and if it is well tolerated. Indeed, a re-
cent Cochrane review recommends that gabapentin be
used this way for the treatment of chronic pain [23].
As above, we discussed possible time points with pa-
tient and stakeholder partners. The times they thought
were most patient-centered for each review are in-
cluded in the sections that follow.
Search methods for identification of studies
We will conduct electronic and additional searches to
identify studies, the results of which will be reported fol-
lowing the PRISMA guidelines [24]. We will search for
the following types of reports (listed by their approxi-
mate level of detail):
1. Study registrations in publicly available databases
(e.g., www.clinicaltrials.gov)
2. Study protocols and statistical analysis plans
3. Short reports (e.g., conference abstracts and posters)
4. Summary data posted on trial registries
5. Peer-reviewed journal articles
6. Dissertations (e.g., masters or doctoral theses)
7. Unpublished manuscripts and reports (e.g., reports
to funders and clinical study reports)
8. Information sent to regulators (e.g., data sent to FDA)
9. Individual participant data
Electronic searches
We will search electronic databases, including the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), CINAHL, Embase, Lilacs, and PubMed. We
will search Medline and PsycInfo for the review of que-
tiapine for bipolar depression. In addition, we will
search the International Clinical Trials Registry Platform
Search Portal (ICTRP) and ClinicalTrials.gov to identify
study protocols and results [25], using generic drug names
and the trade names identified through Micromedex. We
will remove duplicates from ClinicalTrials.gov from the
ICTRP results.
Searching other resources
Reference lists of systematic reviews and included stud-
ies will be checked for additional reports. We will con-
tact authors of included studies to request additional
study reports. We will also contact manufacturers and
search their websites to identify reports.
Regulatory data
We will search for summary data for studies meeting our
eligibility criteria from the FDA website (Drugs@FDA). We
will also search the websites of foreign regulators, including
the European Medicines Agency (EMA), Medicines and
Healthcare Products Regulatory Agency (MHRA, UK),
Therapeutic Goods Administration (TGA, Australia), and
the Pharmaceuticals and Medical Devices Agency (PMDA,
Japan). From each organization’s website, we will download
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the approval letter and related documents for the relevant
indications [26].
On the Drugs@FDA website, we will enter generic
drug names as search terms to identify all related
products. We will then screen records related to each
product to identify potentially relevant documents.
Medical and statistical reviews that might include in-
formation about the methods of results of eligible trials
will be extracted, and we will review the most recent
label for information about eligible trials.
We will write to the FDA and EMA to request any
information they have about the trials we have identified
through our searches (e.g., clinical study reports and in-
dividual participant data), and we will request details of
any other known studies meeting the inclusion criteria.
Individual participant data
For all trials identified, we will request de-identified indi-
vidual participant data and associated documentation
from the study authors and/or sponsor, unless we
already have these files through an alternative source.
For example, individual participant data for several gaba-
pentin trials have been provided as Microsoft Access
files to Kay Dickersin, who provided expert testimony in
litigation against Pfizer, but no codebooks were provided
with them. We will request further details about these
studies (including codebooks to verify definitions of vari-
ables) as appropriate given ongoing litigation and settle-
ment agreements.
We will search for data that have been made publicly
available by manufacturers (e.g., through their web-
sites). We will also search for data that have become
available through other means (e.g., litigation) using the
Drug Industry Document Archive (DIDA), Yale University
Open Data Access (YODA), and PsychRights.org.
Selection of studies
Two reviewers will independently screen titles and
abstracts identified by the electronic searches to deter-
mine which are eligible for inclusion in the review. We
will then obtain and independently screen the full text of
all potentially relevant studies to determine whether they
meet the inclusion criteria. If investigators disagree
about the eligibility of a report, they will discuss the
disagreement with a third investigator to reach consensus
about the study’s eligibility.
If a study cannot be included or excluded based on the
information available in all reports associated with the
study, we will contact the study authors and/or sponsor
for more information to determine eligibility for our
review.
During the study selection process, we will not be
masked to study authors, institutions, journal of publi-
cation, or results.
Results of the search will be documented using modi-
fied PRISMA flowcharts [24].
Outcomes
Reports may include both systematically recorded out-
comes (i.e., those that have been recorded using standard-
ized measures given to all participants) and spontaneously
recorded outcomes (e.g., unexpected outcomes reported
by participants or providers).
Systematically recorded outcomes
From each report, we will record the outcomes, and we
will record if they are identified as “primary,” “secondary,”
and “safety,” using another definition, or not defined
classified.
We will record five elements for each outcome as they
are described in each report [27, 28]:
1. Domain (outcome title);
2. Specific measure (specific scale or instrument);
3. Specific metric (format of the outcome data, such as
value-at-a-time or mean change from baseline);
4. Method of aggregation (how data from each group
will be summarized, such as mean or percent); and
5. Time point (e.g., weeks or months since
randomization).
In addition to these elements, we will record details
about methods of analysis (e.g., handling of missing
data) and the definition of the population for analysis
(e.g., study completers or people starting treatment).
We will extract and analyze results for key domains.
These domains will be selected because they are (1)
commonly measured, (2) likely to be reported selectively
based on previous research, or (3) important to patients.
The reporting of other outcomes will be described, but
meta-analyses will not be conducted.
Spontaneously reported adverse events
In choosing a treatment for neuropathic pain or bipolar
disorder, differences among available drugs in risk of
adverse events may be more important than differences
in average efficacy.
Adverse events can be recorded systematically using
tests or questionnaires; however, trials often record only
adverse events that patients report to doctors or investi-
gators (e.g., on a case report form), which produces data
that are difficult to analyze within and across trials. A
problem related to this method of data collection is that
adverse events may be reported in ad hoc and selective
fashion in clinical trials; thus, systematic reviews may
not pre-specify adverse outcomes or collect adverse
event data systematically. Even when systematic review
authors make every effort to assess effectiveness outcomes
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using scientific methods, they may not be able to apply
the same standards to the synthesis of adverse events [29].
In these reviews, we will extract detailed information
about adverse events from all reports to identify similar-
ities and differences across reports of clinical trials. In
addition to other relevant information (such as the num-
ber of people assigned and included in each analysis), we
will extract the following information about adverse
events:
1. Number (proportion) of participants experiencing
one or more adverse events
2. Number (proportion) of participants who
discontinued treatment because of adverse events
3. Number (proportion) of participants who
discontinued treatment for any reason
4. Number of serious adverse events (i.e., those that could
be classified as serious by the FDA, including death,
life-threatening events, hospitalization, disability or
permanent damage, and important medical events)
5. Specific adverse events. Where possible, these will
be recorded following the classification systems used
by developers at the time trials were conducted.
Most clinical trials would have been analyzed using
either the Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART) or the Medical
Dictionary for Regulatory Activities (MedDRA),
depending on the time they were conducted.
1. For COSTART version IV [30], these are the
following:
(a)Body system: “Essentially anatomic, this body
system classification is sometimes the basis of
search strategy. The classification is hierarchical
in nature.”
(b)Body system subcategories
(c)Mid-level system: “a mid-level pathophysiologic
classification of COSTART for purposes of
categorizing and retrieving information based
on disease associations.” “This section is
hierarchical in arrangement, allowing one to
be very general or more specific and is a
convenient strategy for searching for drug-
induced disease.”
(d)Mid-level system subcategories
(e)Preferred term: A 20-character code used to
identify events
2. For MedDRA [31], these are the following:
(a)System organ class (SOC): “the highest level of
the hierarchy that provides the broadest
concept for data retrieval.” Data are grouped
by etiology, manifestation site, and purpose.
To avoid double-counting preferred terms
(PTs) assigned to more than one SOC, we will
use only the “primary” SOC.
(b)High-level group term (HLGT): “a
superordinate descriptor for one or more HLTs
related by anatomy, pathology, physiology,
etiology, or function”
(c)High-level term (HLT): a superordinate category
that “links PTs related to it by anatomy,
pathology, physiology, etiology, or function.”
(d)Preferred term (PT): “a distinct descriptor
(single medical concept) for a symptom, sign,
disease, diagnosis, therapeutic indication,
investigation, surgical, or medical procedure,
and medical, social, or family history
characteristic.”
(e)Lowest level term (LLT): synonyms for a
preferred term.
Results coded using COSTART will be analyzed at the
level “Preferred term,” “Mid-level system,” and “Body
system.” Results coded using MedDRA will be analyzed
at the level “Preferred term” and above. Additionally, we
will use searches designed to identify clusters of related
symptoms that may not be identifiable using the stand-
ard hierarchy [32].
Adverse events could have been recorded using an-
other hierarchical system, such as WHOART, and results
will be analyzed using these systems where appropriate.
For reports that do not describe adverse events using a
structured classification system, we will record events as
they are described in the reports. Where possible, we
will also compare the terms given to the original re-
porter (e.g., as written on a case report form) and the
preferred terms with which these were associated.
Time points for analysis
We will extract the time at which each outcome was
assessed as described in each report, and we will de-
scribe the planned duration of the included trials.
Effectiveness outcomes (i.e., data about benefits) will
be organized into results at 8 weeks post-randomization
(time window 4–13 weeks), 18 weeks (time window 14–
22 weeks), 27 weeks (time window 23–31 weeks), and
longer times where possible. For each review, we plan to
meta-analyze data for the 8-week time window because
patients may decide if they wish to continue using a
medication during this interval. Additionally, we expect
to have the most data for analysis in the short-term time
window. If sufficient data are available, we will also
analyze outcomes at other times. For each time window,
we will describe how all elements for these outcomes
were reported in each source.
For each of these time windows, key outcomes will be
analyzed in sequential meta-analyses comparing com-
bined effects using different data sources. If results are
reported for a study at multiple times within a window,
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we will use the time closest to 8, 18, or 27 weeks for
meta-analysis.
Adverse events will be analyzed for the same times as
the effectiveness data where possible. Additionally, we will
analyze adverse events occurring closer to randomization
(e.g., 3–4 weeks), which may be important for understand-
ing early discontinuation and compliance.
Because we will analyze only comparators that do not
include the test intervention (e.g., placebo), we do not
expect to find many long-term studies for both ethical
and practical reasons. For example, people who do not
respond to an intervention or placebo after several
months may be unlikely to continue participating in a
trial; even if a trial were to continue beyond acute treat-




Data collection forms will be developed and entered in
the Systematic Review Data Repository (SRDR). These
will be made available through SRDR at the end of the
study.
Data collection forms will be pilot tested. After the ini-
tial versions of the forms have been finalized, data will
be extracted from each report into SRDR. For studies as-
sociated with multiple reports (e.g., journal article and
internal company documents), data will be extracted
from each report for comparison. From each source, we
will record details about the report, study design, start
and end dates, inclusion and exclusion criteria, charac-
teristics of each intervention, participant demographic
and clinical characteristics, outcomes, risk of bias, and
sponsor.
Data will be extracted independently by two reviewers.
Discrepancies will be resolved by consensus and through
discussion with a third reviewer if necessary. The final
dataset will be made publicly available through SRDR at
the end of the study.
For individual participant data
Individual participant data will be accepted in any for-
mat, and these will be analyzed if possible. Where it may
be possible to obtain data in various formats, we will
state our preference for receiving data based on our
familiarity with relevant software and the desirability for
concordance across studies.
Because we do not have codebooks for some gabapen-
tin databases, it is not clear that we will be able to
include all IPD from available sources in our analysis.
Where possible, we will compare the available databases
with case report forms (which often show how and when
data were recorded) and statistical analysis plans (which
often show how data were coded and analyzed) to identify
the variables contained in the databases. From our initial
review, we can see that the databases include participant
numbers, diagnostic information, information about study
site, dates of medical visits, and details about the out-
comes and the types and times of adverse events.
We have also identified some individual participant
data in clinical study reports (CSRs) about quetiapine
for bipolar depression. These reports mainly include
aggregate results, but some reports also contain data for
individual patients, which are organized in tables by par-
ticipant number. We are currently working to extract
information from these reports in an analyzable format.
As with gabapentin, the reports include diagnostic infor-
mation, information about study site, dates of medical
visits, and details about the types and times of adverse
events. Where possible, we will use ABBYY FineReader
software to extract data from PDF files into spreadsheets
for analysis [33].
Whether codebooks are available through the authors
or we have had to reconstruct them, we will check the
data for accuracy. We will first attempt to recreate tables
found in the available reports to examine whether we
have correctly identified study variables, including those
associated with baseline characteristics and results.
Where data have been reformatted for analysis, will also
check a sample of the cells against the original source
for accuracy.
Trials of these drugs have been conducted over two
decades, and it may not be possible to include all IPD in
our analyses from individual investigators because of the
number of datasets received or because some data for-
mats cannot be merged for analysis (e.g., it may not be
possible to combine older formats and newer formats).
If we are not able to include all of the data in the meta-
analysis because they cannot be synthesized in the time
available, we will describe datasets not included in the
analysis.
Confidentiality
De-identified data will be collated in a common database
for each review using fields that are consistent across tri-
als where possible. Until completion of our study, data
will be kept on a local network to which only people
working on this project have access. Unless we find that
participants could be identified using these data, we will
make databases and codebooks publicly available follow-
ing the completion of our study.
In the event that any personally identifiable informa-
tion is found, identifying information will be removed
from the data following Health Insurance Portability and
Accountability Act (HIPAA) guidelines before sharing
the files with others.
We obtained IPD for trials of gabapentin as a result of
litigation for which Kay Dickersin was an expert witness.
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Databases (Microsoft Access files) and documents (PDF
files) containing IPD were provided by Pfizer to the plain-
tiffs’ lawyers without codebooks, and these were then
given to Kay Dickersin to assist with her testimony. The
data have been unsealed, and Pfizer has waived claims of
confidentiality. The quetiapine clinical study reports
include dates of medical tests and narratives about adverse
events that describe the age, sex, and race of participants;
we have also located patient initials in some of the reports.
The clinical study reports that include individual partici-
pant data for quetiapine were made publicly available by
the plaintiffs’ attorneys following a product liability law-
suit, and these are already available on the Internet.
Assessment of risk of bias in included studies
To compare the completeness of reports with respect to
the methodological information they contain, each re-
port will be assessed using the Cochrane Collaboration
Risk of Bias Tool [34]. Two reviewers will independently
rate each report for risk of bias related to sequence gen-
eration, allocation concealment, masking of participants,
masking of outcome assessors, masking of providers,
and incomplete data. We will not rate risk of selective
outcomes reporting in each report, but we will rate each
trial for risk of reporting bias. For each domain, risk of
reporting bias will be described as high, low, or unclear.
Discrepancies will be resolved by consensus and through
discussion with a third reviewer if necessary.
Dealing with missing data
Missing data are unrecorded values that could be mean-
ingful for the analysis and interpretation of a study [35].
In clinical trials, data may be missing for outcomes or
for covariates. For outcomes, a participant who skips
questions on a measure at a given time point may
complete related questions and outcome measures; in
such cases, missing items (i.e., questions) may be im-
puted to calculate the overall scores for measures (i.e.,
questionnaires). In other cases, outcome measures may
be missing in their entirety; missing outcome measures
may be related to missed assessments (e.g., missed visits)
or to discontinuation (e.g., study dropout). For all out-
comes, we will report the amount of missing data and
the reasons for missinginess. Additionally, the following
sections describe how we will handle missing outcomes
in reports of aggregate data and how we will handle IPD
with missing outcomes, including missing items and
missing outcome measures.
In reports of aggregate data
When aggregate analyses of continuous outcomes are
reported only for people providing outcome data as
well as controlling for missing data (e.g., using multiple
imputation), we will analyze the latter. For dichotomous
measures of treatment efficacy, we will conduct an ana-
lysis in which we assume that participants did not respond
to treatment if their outcomes are missing. For dichotom-
ous measures of adverse events, we will conduct an ana-
lysis in which we assume that participants who took at
least one dose of the assigned medication were at risk of
those events. For dichotomous outcomes, we will conduct
sensitivity analyses to evaluate how the results are affected
by different assumptions about missing data.
For secondary (sensitivity) analysis, we will use the
pattern-mixture approach accounting for the uncertainty
due to missing data [36–39]. We will calculate the
adjusted treatment effects for each outcome for which
results are reported without imputation, then synthesize
adjusted and unadjusted treatment effects via standard
meta-analysis across all studies. Adjusted treatment ef-
fects are related to the informative missingness defined
as a ratio (or difference) between missing and observed
treatment effects. We will implement this approach
under various scenarios by considering a wide range of
the informative missingness (that is, we will assume the
missing and observed treatment effects are similar or
different).
For individual participant data
For all trials for which we have IPD, we will attempt to
replicate the analyses performed by the study authors.
Since the time that most studies of gabapentin for
neuropathic pain and quetiapine for bipolar depression
were conducted, researchers have developed new tech-
niques to deal with missing outcome measures. We will
use current best practices for handling missing data to
determine if reanalysis of individual participant data fol-
lowing current best practice might lead to conclusions
that differ from those of the original analyses.
Missing items in individual participant data
For outcome measures (i.e., questionnaires) with mul-
tiple items (i.e., questions), we will attempt to determine
how sensitive the results might be to missing items. For
each treatment group in each trial, we will describe the
mean, maximum, and minimum number of missing
items for each outcome measure where possible. We will
impute missing items using methods described by the
authors where possible. Additionally, we will impute
missing items for standardized scales using standard
coding techniques in the event that the authors did not
impute missing items using standard methods.
Missing outcome measures in individual participant data
We anticipate that two analyses will allow us to replicate
the handling of missing outcome measures (e.g., missing
visits) for most of the analyses conducted by the authors,
complete case analysis and last observation carried forward.
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In the presence of missing data, comparing imputed results
(i.e., using best current methods, as described below) with a
complete case analysis is important for evaluating the con-
sequences of missing data and imputation.
1. Complete case analysis: for each outcome measure,
we will include participants who completed a
specific outcome measure at a specific time point of
interest (e.g., when looking at the Short Form-36
(SF-36) at 6 weeks, we will include all individuals
who completed the SF-36 at that time point). In
addition, we will exclude participants who did not
complete enough items to derive a summary score
for the outcome measure at the specific time point.
2. Last observation carried forward (LOCF): for each
outcome, we will conduct an analysis that includes
all participants who completed that outcome
measure at baseline assessment. If a participant did
not complete an outcome measure at a given point
in time, or if a participant did not complete enough
of an outcome measure to derive a summary score
for that measure, we will impute the outcome
measure by carrying forward the last observation for
that measure. Although single imputation is no
longer recommended for handling missing data, this
analysis will allow us to compare our results with
the results calculated by the trialists [40, 41].
Best current methods
For the meta-analysis, we will estimate the treatment
effects using multiple imputations to impute missing
outcome measures and to account appropriately for the
uncertainty because of missing data [40, 42]. We will
conduct imputations separately for each of the trials. For
each trial, we will impute both individual-level covariates
measured at baseline (including participant characteris-
tics and baseline measures of outcomes) and outcomes
measured at every follow-up time point together using a
“multiple imputation by chained equations” (MICE)
approach, as implemented in the mi impute chained
command in Stata [43]. MICE cycles through the vari-
ables, imputing each variable one at a time, by fitting a
model of that variable as a function of the other vari-
ables in the imputation procedure. This process of
imputing each variable one at a time is then repeated
until the algorithm reaches convergence. The MICE
approach allows each variable to be modeled according
to its own distribution, and it can easily handle data
complications such as variables with restricted ranges
(e.g., age will be at least 18 years and cannot exceed
120 years). In general, we will use logistic regression for
binary variables, multinomial logistic regression for cat-
egorical variables, Poisson regression for count variables,
and a linear regression for continuous variables. For
continuous variables that are not normally distributed,
we will transform the data to be normally distributed to
improve the fit of the imputation models, which will be
linear regression for continuous variables. If we cannot
transform a continuous variable to be normally distrib-
uted, we will use predictive mean matching [44].
The specific variables included in the imputation for
each trial will include treatment group, demographic
characteristics (e.g., sex and age), outcome measures at
baseline and each recorded follow-up (e.g., daily pain
score, present pain intensity, SF-36, SF-MPQ), as well as
other clinical measures that are available across studies
(e.g., heart rate, blood pressure). We will not include
race in the model. In the case of convergence problems
with MICE resulting from the number of variables or
collinearity, we will use stepwise selection models to
assist with the imputations. If there is no computational
limit, we will create 100 imputations for each trial to
achieve high efficiency [45]. We will estimate the treat-
ment effect within each imputed dataset separately, and
then we will combine the estimates for each trial using
the standard multiple imputation combining rules [42].
Then, we will synthesize the combined treatment effect
estimates across all studies as described below (“Data
synthesis“ section).
Imputing all measures together as we will do (i.e., both
baseline and outcome variables) utilizes all data available
for each participant. For example, for a participant with
just one missing follow-up time point, we will impute
that missing value using information from observed
values for that participant at other time points. In
addition, it is seen as the best practice for imputation in
clinical trials to include outcome measures with all the
covariates in the imputation process, as we are planning
to do here (and as described above) [46, 47].
Although White et al. recommend restricting analysis
to individuals reporting outcome measurement after
imputing covariates and outcomes together, we will
estimate treatment effects using all individuals, includ-
ing those with imputed outcomes [48]. In our IPD
meta-analysis, restricting to individuals with observed
outcomes would result in the same treatment effect
estimates as obtained under the complete case analysis.
Sensitivity analyses
1. Pooled imputation: we will conduct a sensitivity
analysis, modified from our MICE approach. In this
sensitivity analysis, we will use a pooled imputation
model in which we implement the multiple
imputation procedure across all trials
simultaneously. This imputation model will include
outcome measures and other variables available for
individual participants in at least three (50 %) of the
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studies for which we have IPD for gabapentin or in
both of the studies for which we have IPD for
quetiapine. For each review, the imputation will be
carried out using a merged dataset that combines
multiple studies. This imputation procedure will
also include study indicators in the imputation
models to account for heterogeneity across studies.
One limitation of this approach is that it will not be
helpful if reported covariates substantially differ
across trials
2. Imputation with non-ignorable missingness:
multiple imputation, as implemented following the
procedures described above (“Best current
methods“ section), assumes that missingness
depends only on the observed data (i.e., missing at
random) and that the missingness is not related to
variables that were not measured. As a secondary
sensitivity analysis, we will consider non-ignorable
missingness (missing not at random (MNAR)),
which assumes that missingness depends on both
observed and unobserved data. To do this, we will
model the outcomes and missingness pattern jointly
using selection or pattern-mixture model
techniques [42]. Using this model, we will estimate
the treatment effect in each study, and we will
conduct a meta-analysis to combine the estimated
treatment effects across all studies as described
below (“Data synthesis“ section). Furthermore, we
will conduc simulation studies to investigate the
impact of different missingness mechanisms with
various missingness rates on treatment effect
estimation in meta-analyses.
Assessment of heterogeneity
To assess clinical and methodological heterogeneity, we
will present the characteristics of studies in tables and
describe the similarity of participants, interventions, out-
comes, and methods across studies.
To assess statistical heterogeneity, we will:
1. Visually inspect forest plots to see if the
confidence intervals of individual studies have
poor overlap—a rough indication of statistical
heterogeneity;
2) Calculate the I2 statistic, which describes the
percentage of observed heterogeneity that would
not be expected by chance [49]. By convention, we
will describe an analysis as having substantial
statistical heterogeneity if its I2 statistic is greater
than 50 %; and
3. Calculate tau, which captures the amount of
heterogeneity on the same scale and unit of the
outcome measure.
Data synthesis
For dichotomous outcomes (other than spontaneously
reported adverse events), we will calculate risk ratios
(RR) within studies and the summary risk ratio across
studies [34]. For continuous outcomes measured on the
same scale in all trials, we will calculate the weighted
mean difference (WMD). For continuous outcomes mea-
sured on more than one scale, we will calculate the
standardized mean difference (Hedges g). In studies
reporting more than one measure of a domain, the most
common measure across studies will be selected for ana-
lysis to minimize methodological heterogeneity. If some
studies do not include the most common measure, we
will select the most similar measure (rather than average
treatment effects within studies).
In meta-analyses that include both aggregate and indi-
vidual participant data, we will conduct two-stage meta-
analyses [50, 51]. Specifically, individual participant data
will be analyzed for each trial and then the results will
be combined with aggregate data across all studies,
assuming that aggregate and individual participant data
estimate the same treatment effects [14, 52]. This
enables us to borrow information from both levels of
data and is the best use of all existing data.
All meta-analyses will be calculated using random-
effects and reported with 95 % confidence intervals (CI)
[53–55].
Spontaneously reported adverse events will be described
in tables, but these will not be analyzed statistically. We
will record the number of events reported in the test (i.e.,
gabapentin or quetiapine) and comparator (e.g., placebo)
groups of every trial report, and we will report the total
number of events for all test and comparator groups for
each data source. Where possible, we will sum individual
participant data at the “Preferred term” level and above
using the COSTART and MedDRA classification systems
(see “Spontaneously reported adverse events“), and we will
record data from other sources as they were reported.
Study design, participant characteristics, and treat-
ment characteristics may affect results, so we will con-
duct a priori subgroup analyses to examine moderators
using aggregate data or individual participant data
where possible [56]. We will investigate differences
between subgroups using a test for interaction (p < 0.1
considered relevant). Residual heterogeneity will be
quantified using I2, which we will describe as substan-
tial if I2 is greater than 50 %.
Comparing multiple sources
For pre-specified outcomes, we will produce a table
showing the results from each study, which will be com-
bined in an overall analysis including results from each
data source, including the following:
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1. Short reports (e.g., conference abstracts and
posters);
2. Peer-reviewed journal articles (about one or more
trials);
3. Summary data posted on trial registries;
4. Dissertations (e.g., masters or doctoral theses);
5. Unpublished manuscripts and reports (e.g., reports
to funders, clinical study reports);
6. Information sent to regulators (e.g., data sent to
FDA); and
7. Individual participant data.
We will examine if the results show evidence of report-
ing bias by comparing multiple data sources for studies
associated with more than one report. For studies with
both sources of data, we will compare the following:
1. Results from individual participant data compared
with CSRs; and
2. Results from CSRs compared with published results.
We will then conduct a series of meta-analyses to
explore the impact of multiple data sources on the over-
all results. We will analyze these results by sequentially
adding or replacing data as follows:
1. Including only results from short reports (e.g.,
conference abstracts and posters);
2. Replacing data from short reports (step 1) with data
from publications in peer-reviewed journals and
adding data from studies reported in peer-reviewed
publications but not short reports;
3. Replacing data from publications (step 2) using
summary data obtained from the authors or
manufacturers, regulators, or trial registries for the
trials included above;
4. Adding data (to step 3) from unpublished trials
using data obtained from regulators, or trial
registries;
5. Adding or replacing data (from step 4) for
unpublished trials with aggregate data obtained
from the authors or manufacturers (e.g., clinical
study reports);
6. Replacing the best available aggregate data for all
studies (step 5) with individual participant data
where available.
If more than one report of a particular type is avail-
able for a trial (e.g., several peer-reviewed publications),
we will include data from all of them in the meta-
analyses. We will note discrepancies where they exist,
and we will analyze results from the main report of a
trial if the main report and other reports are discrepant.
If reports include data for more than one trial, we will
include data reported separately for each trial; we will
not include combined results for these analyses unless
no other estimates are available for the included
studies.
To compare studies that have only been reported in
short reports (e.g., a conference abstract or poster) with
studies that have been reported in greater detail, we will
conduct one further step in this sequence:
7. Removing short reports (e.g., conference abstracts
and posters).
We will investigate if the results for published and un-
published studies differ using the best available data for
each.
By analyzing results in this sequence, we hope to iden-
tify and to quantify differences that are attributable to (1)
information about additional outcomes examined (select-
ive outcome reporting), (2) information from more than
one source for a data item (competing information),
and (3) information about previously hidden trials
(publication bias).
For the main outcome in each review, we will explore
the distribution of possible effects by calculating all
combinations of reports for each outcome and reporting
the range of observed means. We will explore the extent
to which these estimates are influenced by the inclusion
or exclusion of particular reports, paying particular at-
tention to deviations from the mean that represent
clinically important differences in the outcomes under
investigation.
Criteria for selecting studies of gebapentin for
neuropathic pain in adults (CRD42015014037)
Background
Peripheral neuropathy occurs when there is damage to
the peripheral nervous system, the array of nerves that
transmit information from the central nervous system
(brain and spinal cord) to other parts of the body.
There are hundreds of types of peripheral neuropathy,
and the ways that individuals are affected (impaired
function and symptoms) depends on the type of dam-
age. Painful, chronic neuropathies can be caused by
trauma, systemic diseases (e.g., diabetes, kidney disor-
ders, cancer, hormone imbalances, and vitamin defi-
ciencies), infections, immune disorders, chemotherapy,
and other conditions. Between 3 and 10 % of the popu-
lation may be living with painful neuropathy, and pain-
ful neuropathy affects 30 to 50 % of people with
diabetes in particular [57]. Painful neuropathy and its
sequelae, such as loss of sleep, result in reduced quality
of life and high health care costs. For example, the cost
of diabetic peripheral neuropathy has been estimated to
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be US$5 to US$14 billion, which accounts for up to
27 % of the direct medical costs associated with dia-
betes [58].
Gabapentin (Neurontin®) was approved by the FDA for
the treatment of epilepsy in 1993, and it was approved
in 2002 for the treatment of post-herpetic neuralgia (i.e.,
residual pain in people who have had shingles). It is used
“off-label” for a variety of symptoms, including neuro-
pathic and other types of pain.
Types of participants
Studies with adults (18 years and older) with neuro-
pathic pain will be included without restriction by set-
ting (e.g., hospital or outpatient) or comorbidity,
except that participants requiring ventilator support
will be excluded because effects may not be compar-
able to ambulatory populations. Studies including
people with neuropathic pain as well as other condi-
tions will be included if disaggregated data are avail-
able (in a report or from the authors) such that
outcomes can be extracted separately for people with
neuropathic pain (i.e., either individual participant
data or aggregate data).
We will include participants considered to have neuro-
pathic pain secondary to one or more of the following
underlying conditions:
 Cancer (malignancy or chemotherapy induced);
 Central stroke;
 Complex regional pain syndrome;
 Diabetes mellitus;
 Guillain-Barré syndrome;
 Herpes zoster infection;
 HIV infection;
 Multiple sclerosis;
 Nerve compression or entrapment including carpal
tunnel syndrome and vertebral disc prolapse;
 Phantom limb pain;
 Radicular pain, including radiculopathy associated
with spinal stenosis;
 Spinal cord injury;
 Trauma; and
 Trigeminal neuralgia
We will exclude participants considered to have pain
resulting from the following conditions:
 Chronic low back pain other than radicular pain;
 Chronic pelvic pain (which is multifactorial in
etiology and not solely of neuropathic origin);




 Osteoarthritis (pain is considered to be nociceptive
in nature);
 Pre- or post-operative acute pain (e.g., following
thoracotomy or spinal fusion) or pain following
vaginal delivery;
 Restless leg syndrome;
 Spinal stenosis without radiculopathy.
Types of interventions
We will include trials of oral gabapentin alone, or oral
gabapentin in combination with another medication,
with a daily dose of 300 mg gabapentin or above. Studies
in which the dose of gabapentin was escalated until pain
relief was achieved will be eligible. Studies of gabapentin
enacarbil, a prodrug, will be excluded.
Outcomes for sequential meta-analysis
Following consultation with patients and clinicians, a
review of existing trials and recommendations from
the Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT) group [22],
the following key outcomes were selected and will be
extracted from each report and analyzed in a sequen-
tial meta-analysis to compare combined effects for
meta-analyses using different data sources. Other out-
comes will be extracted but not meta-analyzed as de-
scribed below.
1. Pain intensity: severity of daily pain as measured
by any pain scale or instrument. This is often
assessed using a scale with values from 0 (“no
pain”) to 10 (“worst possible pain”), completed
daily. Depending on how pain was measured and
reported in the source documents, we will analyze
it as a continuous outcome or a categorical
outcome.
(a) Improvement in pain
i. 50 % improvement: proportion of participants
in each group with ≥50 % reduction in mean
daily pain intensity for a period of time (e.g.,
1 week) prior to treatment compared with
most recent period of time or a functionally
similar definition.
ii. 30 % improvement: proportion of participants
in each group with ≥30 % reduction in mean
daily pain intensity for a period of time (e.g.,
1 week) prior to treatment compared with
most recent period of time or a functionally
similar definition.
b. Change in pain intensity: mean change in daily
rating for a period of time (e.g., 1 week) prior to
treatment compared with mean daily rating for
most recent week or a functionally similar
definition.
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c. Patient global impression of change: proportion
of participants in each group reporting “very
much improved“ or “much improved”
d. Clinician global impression of change (CGIC or
CGI): proportion of participants “very much
improved” or “much improved”
2. Pain interference: the extent to which pain
prevents normal functioning as measured
by any pain scale or instrument (e.g., the
Multidimensional Pain Inventory Interference
Scale). We will analyze pain interference as a
continuous outcome such as mean change in
interference for a period of time (e.g., 1 week)
prior to treatment compared with mean daily
rating for the most recent period of time or a
functionally similar definition.
3. Sleep disturbance: difficulty sleeping as measured
by any scale or instrument. This is often assessed
using a numeric scale, completed daily, describing
how pain interfered with sleep during the last
24 h; scores may range from 0 (“does not
interfere with sleep”) to 10 (“completely interferes
with sleep”). We will analyze sleep disturbance as
a continuous outcome such as mean change in
daily rating for a period of time (e.g., 1 week)
prior to treatment compared with mean daily
rating for the most recent period of time or a
functionally similar definition.
4. Quality of life (QOL): health-related quality
of life as measured by any scale or instrument
will be analyzed as a continuous outcome
(e.g., change in QOL assessed using the mean
difference from baseline measured on the Short
Form-36). For measures with multiple subscales,
we will include the total in the main analysis
if possible.
In addition to those outcomes included in a sequential
meta-analysis, spontaneously reported adverse events will
be recorded and aggregated using the methods described
above.
Outcomes for descriptive analysis
Definitions of the following outcomes, including the ele-
ments described above [27, 28], will be extracted from each
report. We will use these data to evaluate the completeness
of reporting and to identify differences in outcomes among
reports.
1. Mood, including but not limited to:
(a)Measures of depression (e.g., Beck Depression
Inventory)
(b)Measures of anxiety (e.g., State-Trait Anxiety
Inventory)
(c)Measures of overall mood state (e.g., profile of
mood states) or psychiatric functioning (e.g.,
CORE-OM)
2. Lab tests (e.g., hemoglobin or glucose levels)
3. Evoked pain (e.g., allodynia or hyperalgesia)
4. Consumption of concurrent medication for pain
(sometimes described as “escape” or “rescue”
medication)
5. Time-to-event data related to any domains above
Baseline data to record
To describe the characteristics of participants in each
study, we will extract demographic and clinical charac-
teristics from each report. For the total sample, and for




4. Self-reported race/ethnicity (percentage of non-
white)
5. Drug and alcohol use
6. Study location (country and state or county)
7. Previous response or non-response to medication
(e.g., gabapentin, other pain medications)
8. Pain condition
9. Duration of pain (i.e., time since onset of the
condition)
10.History of anxiety or depressive disorder
Subgroup analysis and investigation of heterogeneity
We will summarize the characteristics of included studies
and describe potential sources of clinical and methodo-
logical heterogeneity among them, and their potential
influence on results.
We will also conduct the following subgroup analyses:
1. Sex (men versus women)
2. Pain condition (post-herpetic pain; diabetic
neuropathy; other types of pain)
3. Daily dose (variable dose studies; fixed doses of 300–
900, 901–1800, 1801–2700, and 2701 mg or more)
Searching for published literature
Databases and trial registries will be searched using the
terms in Appendix 1.
Criteria for selecting studies of quetiapine for bipolar
depression in adults (CRD42015014038)
Background
Bipolar disorder has a lifetime prevalence of 1–4 %
[59, 60]. It is characterized by episodes of depression
and at least one episode of mania or hypomania [61].
Work, family life, and social life are impaired significantly
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by depressive episodes [62, 63]. Because of their sever-
ity and frequency, depressive episodes account for three
times more time spent with disability than manic epi-
sodes [61, 64, 65]. People with bipolar disorder are at
increased risk of suicide compared with the general
population and compared with people who have other
mental health problems [66, 67].
Antipsychotics were developed for the treatment of
acute psychotic episodes, including bipolar mania, for
which there is evidence of short-term efficacy [68].
Quetiapine (Seroquel®) is an antipsychotic that is
derived from dibenzothiazepine. It acts as an antagonist
at serotonergic 5-HT2 receptors and dopaminergic D2
receptors in the central nervous system, but the
method by which it might function as an antidepressant
remains unclear [69, 70]. It is currently recommended
as a first-line choice for treatment of acute bipolar
depression by existing guidelines [71, 72], although it is
associated with outcomes that are undesirable to pa-
tients including daytime sleepiness, cognitive impair-
ment, loss of libido, and rapid weight gain. Quetiapine
and other antipsychotics are also associated with ser-
ious adverse events, including cardiac and metabolic
effects and extrapyramidal symptoms [73, 74].
Types of participants
Studies that include adults (18 years and older) with a
current episode of depression will be included without
restriction by setting (e.g., hospital or outpatient). Par-
ticipants must have been diagnosed with bipolar dis-
order (type I or II) using DSM-III, DSM-IV, DSM-V,
ICD-9, or ICD-10 criteria or an equivalent structured
diagnostic interview. Studies that included only partici-
pants described as having the “rapid cycling” subtype
will be excluded.
Studies including participants with other disorders
(e.g., major depressive disorder and other serious mental
illnesses such as schizophrenia spectrum disorders or
substance abuse) will be included if disaggregated data
are available (in a report or from the authors) such that
outcomes can be extracted separately for people with bi-
polar disorder (i.e., either individual participant data or
aggregate data).
Studies including only participants with both bipolar dis-
order and comorbid disorders (e.g., anxiety or substance
misuse) will be included.
Types of interventions
We will include studies comparing oral quetiapine (in-
cluding extended release) with a daily dose of 100 mg or
above. Studies of norquetiapine, a metabolite of quetia-
pine, will be excluded.
Outcomes for sequential meta-analysis
Following consultation with patients and clinicians and a
review of existing trials, the following key outcomes
were selected and will be extracted from each report and
analyzed in a sequential meta-analysis to compare com-
bined effects for meta-analyses using different data
sources. Other outcomes will be extracted but not meta-
analyzed as described below.
1. Depression: symptoms of depression as measured
by any scale or instrument. Depending on how
depression was measured and reported in the
source documents, we will analyze it as a
continuous outcome or a categorical outcome.
(a) Improvement in symptoms (e.g., proportion of
participants reporting ≥50 % reduction in
depression as measured using the Hamilton Rating
Scale for Depression (HAM-D) or Montgomery-
Åsberg Depression Rating Scale (MADRS))
(b)Change in symptoms of depression (e.g., mean
difference from baseline on the HAM-D,
MADRS, or another depression rating scale)
2. Functioning: ability to participate in social,
occupational, and family life as measured by any
scale or instrument will be analyzed as a continuous
outcome (e.g., change from baseline on the Global
Assessment of Functioning scale).
3. Quality of life: health-related quality of life as mea-
sured by any scale or instrument will be analyzed as
a continuous outcome (e.g., change in QOL assessed
using the mean difference from baseline measured
on the Short Form-36). For measures with multiple
subscales, we will include the total in the main ana-
lysis if possible.
4. Anxiety: symptoms of anxiety as measured by any
scale or instrument. Depending on how anxiety was
measured and reported in the source documents, we
will analyze it as a continuous outcome or a
categorical outcome.
(a) Improvement in symptoms (e.g., proportion of
participants reporting ≥50 % reduction in anxiety
as measured using the Hamilton Rating Scale for
Anxiety)
(b)Change in symptoms of anxiety (e.g., mean
difference from baseline on the HAM-A or
another anxiety rating scale)
5. Sleep
(a)Proportion of participants using sleep medication
(b)Change in sleep (e.g., mean difference from baseline
on the Pittsburgh Sleep Quality Index, HAM-D
insomnia items, or another measure of sleep)
6. Weight gain (we will combine measures of weight
and body mass index because the height of adults is
not expected to change during clinical trials.)
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(a)Measured on a continuous scale, e.g., mean
change from baseline or a value-at-a-time
(b)Measured categorically such as proportion of
participants gaining 2 or 5 % of their baseline weight
7. Psychiatric hospitalization (e.g., proportion of
participants admitted to hospital)
8. Suicide
(a)Proportion of participants completing suicide
(b)Proportion of participants attempting suicide
(c)Proportion of participants with suicidal intent or
suicidal ideation
In addition to those outcomes included in a sequential
meta-analysis, spontaneously reported adverse events will
be recorded and aggregated using the methods described
above.
Outcomes for descriptive analysis
This review focuses on the use of quetiapine for acute
episodes, so adverse events associated with long-term
use might not be observed. We do not expect to find
evidence about outcomes like cataracts that develop
over a period longer than the duration of an acute de-
pressive episode. In acute treatment trials, blood tests
and vital signs may be monitored to identify increased
risk of adverse events, including serious adverse
events.
Definitions of the following outcomes, including the
elements described above [27, 28], will be extracted from
each report. We will use these data to evaluate the com-
pleteness of reporting and to identify differences in out-
comes among reports.
1. Metabolic effects
(a)Proportion of participants with new diagnosis of
diabetes mellitus type II
(b)Waist circumference
i. Measured on a continuous scale, e.g., mean
change from baseline or a value-at-a-time
ii. Measured categorically such as proportion of
participants with increase ≥5 cm
(c)Fasting glucose
i. Measured on a continuous scale, e.g., mean
change from baseline or a value-at-a-time
ii. Measured categorically, e.g., proportion of
participants with fasting glucose ≥100 mg/dL
(hyperglycemia) and proportion of participants
with fasting glucose ≥126 mg/dL
2. Endocrine effects
(a)Proportion of participants reporting loss of interest
in sex or sexual dysfunction (e.g., impotence,
anorgasmia)
(b)Proportion of women reporting irregular or
missed menstrual cycle
(c)Proportion of men reporting gynecomastia
(swelling of the breast tissue)
(d)Serum prolactin levels measured on a continuous
scale, e.g., mean change from baseline or a
value-at-a-time
3. Extrapyramidal symptoms (tardive dyskinesia,
dystonia, akathisia)
(a) Incident cases: proportion of participants
experiencing extrapyramidal symptoms (e.g.,
spasms, tremor, or involuntary movement), who
did not have symptoms at baseline. For example,
proportion of participants exceeding a total
score of 3 on the Modified Simpson-Angus Scale
(MSAS) [75].
(b)Measured on a continuous scale, e.g., mean
change from baseline or a value-at-a-time on the
Involuntary Movement Scale, Condensed User’s
Scale, Simpson-Angus Scale, or Barnes Akathesia
Rating Scale.
4. Cardiovascular effects
(a)Mortality because of cardiac event
(b)Incidence of myocardial infarction
(c)QTc interval prolongation
i. Measured on a continuous scale, e.g., mean
change from baseline or a value-at-a-time
ii. Measured categorically, e.g., proportion of
participants with a prolonged QTc interval.
Where possible, we will define this as ≥450 ms
in men and ≥ 460 ms in women [76]
(d)Blood pressure
i. Mean change from baseline or value-at-a-time
ii. Incidence of orthostatic hypotension (e.g.,
decrease in systolic BP ≥20 mm Hg or decrease
in diastolic BP ≥10 mm Hg within 3 min after
standing from sitting/supine position)
5. Cholesterol
(a)Triglyerides measured continuously, e.g., mean
change from baseline or a value-at-a-time
(b)Triglyerides measured categorically, e.g.,
proportion of participants with ≥150 mg/dL and
proportion of participants with ≥200 mg/dL
(c)Total cholesterol measured continuously, e.g.,
mean change from baseline or a value-at-a-time
(d)Total cholesterol measured categorically, e.g.,
proportion of participants with ≥200 mg/dL
6. Immune effects
(a) Incidence of infection
(b)Incidence of low neutrophil count, e.g., absolute
neutrophil count (ANC) <100/ml)
7. Mania: symptoms of mania and hypomania as
measured by any scale or instrument. Depending on
how mania was measured and reported in the
source documents, we will analyze it as a continuous
outcome or a categorical outcome.
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(a)Worsening of symptoms, e.g., proportion of
participants scoring ≥16 or ≥20 on the Young
Mania Rating Scale (YMRS) [77, 78]
(b)Change in symptoms of mania, e.g., mean
difference from baseline on the YMRS or another
depression rating scale
8. Neuroleptic malignant syndrome (an adverse
reaction characterized by fever, muscle rigidity, and
cognitive and autonomic abnormalities)
9. Time-to-event data related to any domains above
Baseline data to record
To describe the characteristics of participants in each
study, we will extract demographic and clinical charac-
teristics from each report. For the total sample, and for




4. Self-reported race/ethnicity (percentage of non-white)
5. Drug and alcohol use
6. Study location (country and state or county)
7. Previous response or non-response to medication
(e.g., quetiapine, other antipsychotics)
8. Concurrent psychiatric medication use (which will
be described individually and in classes, such as
antipsychotics, anticonvulsants, selective serotonin
reuptake inhibitors, tricyclics, MAOIs, and lithium)
9. Duration of current episode (i.e., time since onset)
10.Number of mood episodes in the last year
11.Comorbid psychiatric conditions (e.g., proportion of
people with an anxiety disorder, substance use
disorder, personality disorder, or other mood
disorder)
Subgroup analysis and investigation of heterogeneity
We will summarize the characteristics of included studies
and describe potential sources of clinical and methodo-
logical heterogeneity between them and their potential
influence on results.
We will conduct the following subgroup analyses:
1. Sex (men versus women)
2. Type of bipolar disorder (type I compared with type II)
3. Use of other concurrent medication (e.g., quetiapine
as adjunct compared with quetiapine monotherapy)
4. Daily dose (variable dose studies; fixed doses of 100–
300, 301–600, 601–900, and over 900 mg)
Searching for published literature
Databases and trial registries will be searched using the
terms in Appendix 2.
Discussion
This study is now underway. We have identified out-
comes for both reviews, conducted literature searches,
and begin data extraction.
Protocol amendments
If this protocol is amended, we will record a description
and the date of each amendment and we will describe
these changes with the final report.
Appendix 1
Gabapentin for neuropathic pain searches
Searching for published literature
Databases will be searched using the following terms.
PubMed
((((((((Pain Measurement[Mesh] OR Pain[Mesh] OR
pain[tiab]))
AND
((“Amputation”[Mesh] OR “Amputation Stumps”[-
Mesh] OR “Amputation, Traumatic”[Mesh] OR “Central
Nervous System Diseases”[Mesh] OR “Diabetes Mellit
us”[Mesh] OR “Diabetes Mellitus, Type 2”[Mesh] OR
“Diabetes Mellitus, Type 1”[Mesh] OR “Diabetes Comp
lications”[Mesh] OR “Guillain-Barre Syndrome”[Mesh]
OR “HIV Seropositivity”[Mesh] OR “HIV Infections”[-
Mesh] OR “Acquired Immunodeficiency Syndrome”[M
esh] OR “Multiple Sclerosis”[Mesh] OR “Neoplasms”
[Mesh] OR “Neoplasm Recurrence, Local”[Mesh] OR
“Neoplasm Metastasis”[Mesh] OR “Neoplasm Invasiven
ess”[Mesh] OR “Drug Resistance, Neoplasm”[Mesh] OR
“Nervous System Neoplasms”[Mesh] OR “Causalgia”[M
esh] OR “Complex Regional Pain Syndromes”[Mesh] OR
“Reflex Sympathetic Dystrophy”[Mesh] OR “Phantom
Limb”[Mesh] OR “Trauma, Nervous System”[Mesh]
OR “Spinal Cord Injuries”[Mesh] OR “Thoracic Injuries
”[Mesh] OR “Stroke”[Mesh] OR “Trigeminal Neura
lgia”[Mesh] OR “Carpal Tunnel Syndrome”[Mesh])
OR (amputation[tiab] OR amputations[tiab] OR traum
atic[tiab] OR trauma[tiab] OR diabetes[tiab] OR GBS
[tiab] OR “demyelinating polyneuropathy”[tiab] OR “demy
elinating polyneuropathies”[tiab] OR “Acute Autoimmune
Neuropathy”[tiab] OR “acute autoimmune neuropathies”[t
iab] OR “acute inflammatory polyneuropathy”[tiab] OR
“acute inflammatory polyneuropathies”[tiab] OR “guillain
barre syndrome”[tiab] OR “guillaine barre syndrome”[tiab]
OR “guillainbarre syndrome”[tiab] OR HIV[tiab] OR
AIDS[tiab] OR “human immunodeficiency virus”[tiab] OR
“multiple sclerosis”[tiab] OR tumor[tiab] OR tumour[tiab]
OR cancer[tiab] OR malignancy[tiab] OR carcinoma[tiab]
OR neoplasm[tiab] OR tumors[tiab] OR tumours[tiab]
OR cancers[tiab] OR malignancies[tiab] OR carcinomas[ti
ab] OR neoplasms[tiab] OR neuralgia[tiab] OR neural-
gias[tiab] OR “phantom limb pain”[tiab] OR “phantom
limb pains”[tiab] OR “complex regional pain syndrome”[t
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iab] OR “complex regional pain syndromes”[tiab] OR
CRPS[tiab] OR causalgia[tiab] OR “spinal cord injury”[ti
ab] OR stroke[tiab] OR strokes[tiab] OR paralysis[tiab]
OR “reflex sympathetic dystrophy”[tiab] OR “tic douloure
ux”[tiab] OR “carpal tunnel syndrome”[tiab])))) OR
((“Paresthesia”[Mesh] OR “Somatosensory Disorders”[M
esh] OR “Neuralgia”[Mesh] OR “Polyradiculoneuropa
thy”[Mesh] OR “Paraneoplastic Polyneuropathy”[Mesh]
OR “Peripheral Nervous System Diseases/drug therapy”[
Majr]) OR (paresthesia[tiab] OR paraesthesia[tiab] OR
paresthesias[tiab] OR paraesthesias[tiab] OR neuropathic
pain[tiab] OR painful neuropathy[tiab] OR neuropathic
chronic pain[tiab]))) OR ((Diabetic Neuropathies[Mesh]
OR “Herpes Zoster/complications”[Mesh] OR “Neuralgia,
Postherpetic”[Mesh]) OR (“diabetes complication”[tiab]
OR “diabetes complications”[tiab] OR “diabetic complicati
on”[tiab] OR “diabetic complications”[tiab] OR “diabetic neu
ropathy”[tiab] OR PDN[tiab] OR “diabetic neuropathies”[-
tiab] OR “diabetic polyneuropathy”[tiab] OR “diabetic poly-
neuropathies”[tiab] OR “diabetic autonomic neuropathy”
[tiab] OR “diabetic autonomic neuropathies”[tiab] OR “dia-
betic mononeuropathy”[tiab] OR “diabetic mononeuropa-
thies”[tiab] OR “diabetic amyotrophy”[tiab] OR herpes[tiab]
OR shingles[tiab] OR zoster[tiab] OR HSV[tiab] OR “dia-
betic neuropathic pain”[tiab] OR DPN[tiab] OR PHN[tiab]
OR “neuropathic cancer pain”[tiab] OR “chemotherapy-in-
duced peripheral neuropathy”[tiab] OR CINP[tiab]))))
AND
((Amines[Mesh] OR “Cyclohexanecarboxylic Acids”[M
esh] OR “gamma-Aminobutyric Acid”[Mesh:noexp] OR
“GABA Agonists”[Mesh] OR “GABA Agents”[Mesh] OR
“Anticonvulsants”[Mesh] OR “Anticonvulsants”[Pharmac
ological Action] OR Epilepsy/drug effects[Mesh] OR “Epile
psy/drug therapy”[Mesh] OR “Epilepsy/therapy”[Mesh])
OR (anticonvulsant[tiab] OR anticonvulsants[tiab] OR
“anti-convulsant”[tiab] OR “anti-convulsants”[tiab] OR
“antiepileptic drug”[tiab] OR “antiepileptic drugs”[tiab] OR
“anti-epileptic drug”[tiab] OR “anti-epileptic drugs”[tiab]
OR “antiseizure drug”[tiab] OR “antiseizure drugs”[tiab]
OR “anti-seizure drug”[tiab] OR “anti-seizure drugs”[tiab]
OR “antiseizure agent”[tiab] OR “antiseizure agents”[tiab]
OR “anti-seizure agent”[tiab] OR “anti-seizure agents”[tiab]
OR “antiepileptic agent”[tiab] OR “antiepileptic agents”[t
iab] OR “anti-epileptic agent”[tiab] OR “anti-epileptic
agents”[tiab] OR gabapentin[tiab] OR Neurontin[tiab])))
AND
(randomized controlled trial[pt] OR controlled clinical
trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical
trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti])
NOT (Animals[mesh] NOT humans[mesh])
Embase.com
Combination of concepts
#1 Pain AND Conditions
#2 Neuropathic pain OR Condition-specific neuro-
pathic pain
#3 Drugs
#4 Cochrane UK RCT Terms
#5 (#1 OR #2) AND #3 AND #4
Pain
“pain”/exp OR “chronic pain”/exp OR “pain assessment”/
exp OR “neuralgia”/exp OR “visual analog scale”/exp OR
pain:ab,ti OR “visual analog scale”:ab,ti OR “vas”:ab,ti OR
“visual analogue scale”:ab,ti OR neuralgia:ab,ti
Neuropathic pain
paresthesia”/exp OR “neuralgia”/exp OR “neuropathic
pain”/exp OR “somatosensory disorder”/exp OR “poly-
neuropathy”/exp OR “polyradiculoneuropathy”/exp OR
“peripheral nerve injury”/exp OR “neuropathy”/exp OR
“dysesthesia”/exp OR “peripheral neuropathy”/exp OR
“sensory neuropathy”/exp OR “sensory dysfunction”/exp
OR neuralgia:ab,ti OR neuralgias:ab,ti OR “neuropathic
pain”:ab,ti OR paresthesia:ab,ti OR paraesthesia:ab,ti OR
paresthesias:ab,ti OR paraesthesias:ab,ti OR polyneuro-
pathy:ab,ti OR polyneuropathies:ab,ti OR polyradiculo-
neuropathy:ab,ti OR polyradiculoneuropathies:ab,ti OR
dysesthesia:ab,ti OR dysesthesias:ab,ti
Conditions
“radicular pain”/exp OR “radiculopathy”/exp OR “low back
pain”/exp OR “diabetes mellitus”/de OR “non insulin
dependent diabetes mellitus”/exp OR “guillain barre syn-
drome”/exp OR “herpes zoster”/exp OR “human immuno-
deficiency virus”/de OR “human immunodeficiency virus
infection”/de OR “multiple sclerosis”/exp OR “malignant
neoplastic disease”/exp OR “cancer pain”/exp OR “postop-
erative pain”/exp OR “sensory neuropathy”/exp OR “per-
ipheral nerve injury”/exp OR “causalgia”/exp OR “complex
regional pain syndrome type 1”/exp OR “spinal cord
injury”/exp OR “vertebral canal stenosis”/exp OR “intermit-
tent claudication”/exp OR “nervous system injury”/exp OR
“stroke”/exp OR “paraplegia”/exp OR “phantom pain”/exp
OR “amputation”/exp OR “carpal tunnel syndrome”/exp
OR “trigeminus neuralgia”/exp OR amputation:ab,ti OR
amputations:ab,ti OR “radicular pain”:ab,ti OR radicu-
lopathy:ab,ti OR radiculopathies:ab,ti OR “low back pai-
n”:ab,ti OR “lower back pain”:ab,ti OR diabetes:ab,ti OR
“guillain-barre syndrome”:ab,ti OR “guillainbarre syn-
drome”:ab,ti OR “guillaine barre syndrome”:ab,ti OR
gbs:ab,ti OR “demyelinating polyneuropathy”:ab,ti OR
“demyelinating polyneuropathies”:ab,ti OR “acute auto-
immune neuropathy”:ab,ti OR “acute autoimmune neuro-
pathies”:ab,ti OR “acute inflammatory polyneuropathy”:ab,ti
OR “acute inflammatory polyneuropathies”:ab,ti OR herpe-
s:ab,ti OR shingles:ab,ti OR zoster:ab,ti OR hsv:ab,ti OR
hiv:ab,ti OR aids:ab,ti OR “human immunodeficiency
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virus”:ab,ti OR “multiple sclerosis”:ab,ti OR cancer:ab,ti OR
tumor:ab,ti OR tumour:ab,ti OR malignancy:ab,ti OR
carcinoma:ab,ti OR neoplasm:ab,ti OR tumors:ab,ti OR
tumours:ab,ti OR cancers:ab,ti OR malignancies:ab,ti OR
carcinomas:ab,ti OR neoplasms:ab,ti OR “phantom limb
pain”:ab,ti OR “complex regional pain syndrome”:ab,ti OR
crps:ab,ti OR causalgia:ab,ti OR “spinal cord injury”:ab,ti
OR stroke:ab,ti OR strokes:ab,ti OR paralysis:ab,ti OR “car-
pal tunnel syndrome”:ab,ti OR “trigeminal neuralgia”:ab,ti
OR “tic douloureux”:ab,ti
Condition-specific neuropathic pain concept
“diabetic neuropathy”/exp OR “postherpetic neuralgia”/
exp OR “chemotherapy-induced peripheral neuropathy”
OR “neuropathic cancer pain” OR “cancer pain”/exp
OR “chronic post-thoractomy pain” OR “phantom
pain”/exp OR “posttraumatic pain”/exp OR “postopera-
tive pain”/exp OR “diabetes complication”:ab,ti OR
“diabetes complications”:ab,ti OR “diabetic complicatio-
n”:ab,ti OR “diabetic complications”:ab,ti OR “diabetic
neuropathy”:ab,ti OR “diabetic neuropathies”:ab,ti OR
“diabetic neuralgia”:ab,ti OR “diabetic neuralgias”:ab,ti
OR pdn:ab,ti OR dpn:ab,ti OR “diabetic polyneuro-
pathy”:ab,ti OR “diabetic polyneuropathies”:ab,ti OR
“diabetic autonomic neuropathy”:ab,ti OR “diabetic
autonomic neuropathies”:ab,ti OR “diabetic asymmetric
polyneuropathy”:ab,ti OR “diabetic asymmetric poly-
neuropathies”:ab,ti OR “diabetic mononeuropathy”:ab,ti
OR “diabetic mononeuropathies”:ab,ti OR “diabetic
amyotrophy”:ab,ti OR “post-herpetic neuralgia”:ab,ti OR
“post-herpetic neuralgias”:ab,ti OR “postherpetic neur-
algia”:ab,ti OR “postherpetic neuralgias”:ab,ti OR “post-
herpetic neuropathic pain”:ab,ti OR “postherpetic
neuropathic pain”:ab,ti OR (“chemotherapy”:ab,ti AND
“neuropathic pain”:ab,ti) OR “cancer pain”:ab,ti OR
(“chronic”:ab,ti AND (“postoperative”:ab,ti OR “post-
operative”:ab,ti OR “post operative”:ab,ti OR “postsurgi-
cal”:ab,ti OR “post-surgical”:ab,ti) AND “pain”:ab,ti)
Drug term
“4 aminobutyric acid”/de OR “cyclohexanecarboxylic
acid derivative”/exp OR “gabapentin”/exp OR “gabapen-
tin enacarbil”/exp OR “anticonvulsive agent”/de OR
anticonvulsant:ab,ti OR anticonvulsants:ab,ti OR “anti-
convulsant”:ab,ti OR “anti-convulsants”:ab,ti OR “antiep-
ileptic drug”:ab,ti OR “antiepileptic drugs”:ab,ti OR
“anti-epileptic drug”:ab,ti OR “anti-epileptic drugs”:ab,ti
OR “antiseizure drug”:ab,ti OR “antiseizure drugs”:ab,ti
OR “anti-seizure drug”:ab,ti OR “anti-seizure drugs”:ab,ti
OR “antiseizure agent”:ab,ti OR “antiseizure agents”:ab,ti
OR “anti-seizure agent”:ab,ti OR “anti-seizure agents”:ab,ti
OR “antiepileptic agent”:ab,ti OR “antiepileptic agent-
s”:ab,ti OR “anti-epileptic agent”:ab,ti OR “anti-epileptic
agents”:ab,ti OR gabapentin:ab,ti OR Neurontin:ab,ti
Cochrane UK RCT Terms for Embase
random* OR factorial* OR crossover* OR cross NEXT/1
over* OR placebo* OR doubl* NEXT/1 blind* OR singl*
NEXT/1 blind* OR assign* OR allocate* OR volunteer*
OR “crossover procedure”/exp OR “double blind proced-
ure”/exp OR “randomized controlled trial”/exp OR
“single blind procedure”/exp
Central
#1 MeSH descriptor: [Pain] explode all trees
#2 MeSH descriptor: [Pain Measurement] explode all
trees
#3 “pain” (Word variations have been searched)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Amputation] explode all trees
#6 MeSH descriptor: [Amputation Stumps] explode all
trees
#7 MeSH descriptor: [Amputation, Traumatic] explode
all trees
#8 MeSH descriptor: [Central Nervous System Diseases]
explode all trees
#9 MeSH descriptor: [Diabetes Mellitus] explode all
trees
#10 MeSH descriptor: [Diabetes Complications] explode
all trees
#11 MeSH descriptor: [Guillain-Barre Syndrome] explode
all trees
#12 MeSH descriptor: [HIV Seropositivity] explode all
trees
#13 MeSH descriptor: [HIV Infections] explode all
trees
#14 MeSH descriptor: [Acquired Immunodeficiency
Syndrome] explode all trees
#15 MeSH descriptor: [Multiple Sclerosis] explode all
trees
#16 MeSH descriptor: [Neoplasms] explode all trees
#17 MeSH descriptor: [Neoplasm Recurrence, Local]
explode all trees
#18 MeSH descriptor: [Neoplasm Metastasis] explode
all trees
#19 MeSH descriptor: [Neoplasm Invasiveness] explode
all trees
#20 MeSH descriptor: [Drug Resistance, Neoplasm]
explode all trees
#21 MeSH descriptor: [Nervous System Neoplasms]
explode all trees
#22 MeSH descriptor: [Causalgia] explode all trees
#23 MeSH descriptor: [Complex Regional Pain
Syndromes] explode all trees
#24 MeSH descriptor: [Reflex Sympathetic Dystrophy]
explode all trees
#25 MeSH descriptor: [Phantom Limb] explode all trees
#26 MeSH descriptor: [Trauma, Nervous System]
explode all trees
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#27 MeSH descriptor: [Spinal Cord Injuries] explode
all trees
#28 MeSH descriptor: [Thoracic Injuries] explode all
trees
#29 MeSH descriptor: [Stroke] explode all trees
#30 MeSH descriptor: [Trigeminal Neuralgia] explode
all trees
#31 MeSH descriptor: [Carpal Tunnel Syndrome]
explode all trees
#32 (amputation or amputations or traumatic or trauma
or diabetes or GBS or “demyelinating polyneuropathy” or
“demyelinating polyneuropathies” or “Acute Autoimmune
Neuropathy” or “acute autoimmune neuropathies” or
“acute inflammatory polyneuropathy” or “acute inflamma-
tory polyneuropathies” or “guillain barre syndrome” or
“guillaine barre syndrome” or “guillainbarre syndrome” or
HIV or AIDS or “human immunodeficiency virus” or
“multiple sclerosis” or tumor or tumour or cancer or ma-
lignancy or carcinoma or neoplasm or tumors or tumours
or cancers or malignancies or carcinomas or neoplasms or
neuralgia or neuralgias or “phantom limb pain” or “phan-
tom limb pains” or “complex regional pain syndrome” or
“complex regional pain syndromes” or CRPS or causalgia
or “spinal cord injury” or stroke or strokes or paralysis or
“reflex sympathetic dystrophy” or “reflex sympathetic dys-
trophies” or “tic douloureux” or “carpal tunnel syndrome”)
(Word variations have been searched)
#33 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or
#13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or
#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or
#29 or #30 or #31 or #32
#34 #4 and #33
#35 MeSH descriptor: [Paresthesia] explode all trees
#36 MeSH descriptor: [Somatosensory Disorders]
explode all trees
#37 MeSH descriptor: [Neuralgia] explode all trees
#38 MeSH descriptor: [Polyradiculoneuropathy] explode
all trees
#39 MeSH descriptor: [Paraneoplastic Polyneuropathy]
explode all trees
#40 MeSH descriptor: [Peripheral Nervous System
Diseases] explode all trees and with qualifier(s): [Drug
therapy - DT]
#41 (paresthesia or paraesthesia or paresthesias or par-
aesthesias or neuropathic pain or painful neuropathy or
neuropathic chronic pain) (Word variations have been
searched)
#42 #35 or #36 or #37 or #38 or #39 or #40 or #41
#43 MeSH descriptor: [Diabetic Neuropathies] explode
all trees
#44 MeSH descriptor: [Herpes Zoster] explode all
trees and with qualifier(s): [Complications - CO]
#45 MeSH descriptor: [Neuralgia, Postherpetic] explode
all trees
#46 (“diabetes complication” or “diabetes complications”
or “diabetic complication” or “diabetic complications” or
“diabetic neuropathy” or PDN or “diabetic neuropathies” or
“diabetic polyneuropathy” or “diabetic polyneuropathies” or
“diabetic autonomic neuropathy” or “diabetic autonomic
neuropathies” or “diabetic mononeuropathy” or “diabetic
mononeuropathies” or “diabetic amyotrophy” or herpes or
shingles or zoster or HSV or “diabetic neuropathic pain” or
DPN or PHN or “neuropathic cancer pain” or “chemother-
apy-induced peripheral neuropathy” or CINP) (Word varia-
tions have been searched)
#47 #43 or #44 or #45 or #46
#48 #34 or #42 or #47
#49 MeSH descriptor: [Amines] explode all trees
#50 MeSH descriptor: [Cyclohexanecarboxylic Acids]
explode all trees
#51 MeSH descriptor: [gamma-Aminobutyric Acid]
this term only
#52 MeSH descriptor: [GABA Agonists] explode all trees
#53 MeSH descriptor: [GABA Agents] explode all trees
#54 MeSH descriptor: [Anticonvulsants] explode all
trees
#55 MeSH descriptor: [Epilepsy] explode all trees
#56 (anticonvulsant or anticonvulsants or “anti-con-
vulsant” or “anti-convulsants” or “antiepileptic drug” or
“antiepileptic drugs” or “anti-epileptic drug” or “anti-
epileptic drugs” or “antiseizure drug” or “antiseizure
drugs” or “anti-seizure drug” or “anti-seizure drugs” or
“antiseizure agent” or “antiseizure agents” or “anti-seiz-
ure agent” or “anti-seizure agents” or “antiepileptic
agent” or “antiepileptic agents” or “anti-epileptic agent”
or “anti-epileptic agents” or gabapentin or Neurontin)
(Word variations have been searched)
#57 #49 or #50 or #51 or #52 or #53 or #54 or #55
or #56
#58 #48 and #57
CINAHL (Ebsco)
Combination of concepts
#1 Pain AND Conditions
#2 Neuropathic pain OR Condition-specific neuro-
pathic pain
#3 Drugs
#5 (#1 OR #2) AND #3
Pain concept
(MH “Pain”) OR (MH “Back Pain”) OR (MH “Low
Back Pain”) OR (MH “Facial Pain”) OR (TI pain OR AB
pain)
Neuropathic pain concept
((MH “Paresthesia+“) OR (MH “Somatosensory Disorders
+“) OR (MH “Neuralgia+”) OR (MH “Polyneuropathies+”)
OR (MH “Neuralgia+”)) OR (TI paresthesia OR AB
paresthesia OR TI paraesthesia OR AB paraesthesia OR
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TI paresthesias OR AB paresthesias OR TI paraesthesias
OR AB paraesthesias OR TI neuropathic pain OR AB
neuropathic pain OR TI painful neuropathy OR AB pain-
ful neuropathy OR TI painful neuropathies OR AB painful
neuropathies OR TI neuropathic chronic pain OR AB
neuropathic chronic pain OR TI Polyradiculoneuropathy
OR AB Polyradiculoneuropathy OR TI Polyradiculo-
neuropathies OR AB Polyradiculoneuropathies OR TI
neuralgia OR AB neuralgia OR TI neuralgias OR AB
neuralgias)
Conditions concept
((MH “Amputation+”) OR (MH “Phantom Pain”) OR
(MH “Amputation Stumps”) OR (MH “Amputation,
Traumatic”) OR (MH “Diabetes Mellitus+”) OR (MH
“Diabetes Mellitus, Non-Insulin-Dependent”) OR (MH
“Diabetes Mellitus, Insulin-Dependent”) OR (MH “Guil-
lain-Barre Syndrome”) OR (MH “HIV Seropositivity”)
OR (MH “HIV Infections+“) OR (MH “Acquired
Immunodeficiency Syndrome“) OR (MH “Human
Immunodeficiency Virus+“) OR (MH “Multiple Scler-
osis“) OR (MH “Neoplasms+“) OR (MH “Carcinoma+”)
OR (MH “Neoplasm Recurrence, Local”) OR (MH “Neo-
plasm Metastasis”) OR (MH “Neoplasm Invasiveness”)
OR (MH “Causalgia”) OR (MH “Complex Regional Pain
Syndromes”) OR (MH “Reflex Sympathetic Dystrophy”)
OR (MH “Phantom Limb”) OR (MH “Spinal Cord Injur-
ies+”) OR (MH “Stroke”) OR (MH “Trauma+”) OR (MH
“Trigeminal Neuralgia”) OR (MH “Low Back Pain+”))
OR (TI amputation OR AB amputation OR TI amputa-
tions OR AB amputations OR TI traumatic OR AB trau-
matic OR TI trauma OR AB trauma OR TI diabetes OR
AB diabetes OR TI “guillain barre syndrome” OR AB
“guillain barre syndrome” OR TI “guillaine barre syn-
drome” OR AB “guillaine barre syndrome” OR TI “guil-
lainbarre syndrome” OR AB “guillainbarre syndrome”
OR TI GBS OR AB GBS OR TI “demyelinating poly-
neuropathy” OR AB “demyelinating polyneuropathy” OR
TI “demyelinating polyneuropathies” OR AB “demyelin-
ating polyneuropathies” OR TI “Acute Autoimmune
Neuropathy” OR AB “Acute Autoimmune Neuropathy”
OR TI “acute autoimmune neuropathies” OR AB “acute
autoimmune neuropathies” OR TI “acute inflammatory
polyneuropathy” OR AB “acute inflammatory polyneur-
opathy” OR TI “acute inflammatory polyneuropathies”
OR AB “acute inflammatory polyneuropathies” OR TI
HIV OR AB HIV OR TI AIDS OR AB AIDS OR TI “hu-
man immunodeficiency virus” OR AB “human immuno-
deficiency virus” OR TI “multiple sclerosis” OR AB
“multiple sclerosis” OR TI tumor OR AB tumor OR TI
tumour OR AB tumour OR TI cancer OR AB cancer
OR TI malignancy OR AB malignancy OR TI carcinoma
OR AB carcinoma OR TI tumors OR AB tumors OR TI
tumours OR AB tumours OR TI cancers OR AB cancers
OR TI malignancies OR AB malignancies OR TI carcin-
omas OR AB carcinomas OR TI “phantom limb pain”
OR AB “phantom limb pain” OR TI “complex regional
pain syndrome” OR AB “complex regional pain syn-
drome” OR TI “complex regional pain syndromes” OR
AB “complex regional pain syndromes” OR TI CRPS OR
AB CRPS OR TI causalgia OR AB causalgia OR TI cau-
salgias OR AB causalgias OR TI “spinal cord injury” OR
AB “spinal cord injury” OR TI “spinal cord injuries” OR
AB “spinal cord injuries” OR TI stroke OR AB stroke
OR TI strokes OR AB strokes OR TI paralysis OR AB
paralysis OR TI “reflex sympathetic dystrophy” OR AB
“reflex sympathetic dystrophy” OR TI “reflex sympa-
thetic dystrophies” OR AB “reflex sympathetic dystro-
phies” OR TI “trigeminal neuralgia” OR AB “trigeminal
neuralgia” OR TI “trigeminal neuralgias” OR AB “tri-
geminal neuralgias” OR TI “tic doloreux” OR AB “tic
doloreux” OR TI “Diabetes Complications” OR AB “Dia-
betes Complications”)
Condition-specific neuropathic pain concept
((MH “Diabetic Neuropathies+“) OR (MH “Herpes Zos-
ter+/CO”) OR (MH “Neuralgia, Postherpetic+“) OR
(MH “Cancer Pain+”)) OR (TI “diabetes complication”
OR AB “diabetes complication” OR TI “diabetic compli-
cation” OR AB “diabetic complication” OR TI “diabetic
complications” OR AB “diabetic complications” OR TI
“painful diabetic neuropathy” OR AB “painful diabetic
neuropathy” OR TI “diabetic neuralgia” OR AB “diabetic
neuralgia” OR TI PDN OR AB PDN OR TI “diabetic
neuropathies” OR AB “diabetic neuropathies” OR TI
“diabetic polyneuropathy” OR AB “diabetic polyneurop-
athy” OR TI “diabetic polyneuropathies” OR AB “dia-
betic polyneuropathies” OR TI “diabetic autonomic
neuropathy” OR AB “diabetic autonomic neuropathy”
OR TI “diabetic mononeuropathy” OR AB “diabetic
mononeuropathy” OR TI “diabetic mononeuropathies”
OR AB “diabetic mononeuropathies” OR TI “diabetic
amyotrophy” OR AB “diabetic amyotrophy” OR TI her-
pes OR AB herpes OR TI shingles OR AB shingles OR
TI zoster OR AB zoster OR TI HSV OR AB HSV OR TI
“diabetic neuropathic pain” OR AB “diabetic neuropathic
pain” OR TI DPN “ OR AB DPN OR TI PHN OR AB
PHN OR TI “neuropathic cancer pain” OR AB “neuro-
pathic cancer pain” OR TI “neuropathic pain syndrome”
OR AB “neuropathic pain syndrome” OR TI “neuro-
pathic pain syndromes” OR AB “neuropathic pain syn-
dromes” OR TI “chemotherapy-induced neuropathic
pain” OR AB “chemotherapy-induced neuropathic pain”
OR TI “chemotherapy-induced peripheral neuropathy”
OR AB “chemotherapy-induced peripheral neuropathy”
OR TI “chemotherapy induced neuropathic pain “ OR
AB “chemotherapy induced neuropathic pain” OR TI
CINP OR AB CINP)
Mayo-Wilson et al. Systematic Reviews  (2015) 4:143 Page 21 of 28
Drugs concept for gabapentin alone
((MH “GABA”) OR (MH “GABA Agonists+“) OR (MH
“GABA Agents+”) OR (MH “Anticonvulsants+“) OR
(MH “Epilepsy+/DT/TH”) OR (MH “Gabapentin”)) OR
(TI anticonvulsant OR AB anticonvulsant OR TI anti-
convulsants OR AB anticonvulsants OR TI “anti-convul-
sant” OR AB “anti-convulsant” OR TI “anti-convulsants”
OR AB “anti-convulsants” OR TI “antiepileptic drug”
OR AB “antiepileptic drug” OR TI “antiepileptic drugs”
OR AB “antiepileptic drugs” OR TI “anti-epileptic drug”
OR AB “anti-epileptic drug” OR TI “anti-epileptic drugs”
OR AB “anti-epileptic drugs” OR TI “antiseizure drug”
OR AB “antiseizure drug” OR TI “antiseizure drugs” OR
AB “antiseizure drugs” OR TI “anti-seizure agent” OR
AB “anti-seizure agent” OR TI “anti-seizure agents” OR
AB “anti-seizure agents” OR TI “antiepileptic agent” OR
AB “antiepileptic agent” OR TI “antiepileptic agents” OR
AB “antiepileptic agents” OR TI “anti-epileptic agent”
OR AB “anti-epileptic agent” OR TI “anti-epileptic
agents” OR AB “anti-epileptic agents” OR TI gabapentin
OR AB gabapentin OR TI Neurontin OR AB Neurontin)
LILACS
(((pain OR C10.597.617$ OR C23.888.646$ OR
E01.370.600.550.324) AND (amputation OR amputations
OR E04.555.080$ OR traumatic OR trauma OR diabetes
OR “guillain-barre syndrome” OR “guillaine-barre syn-
drome” OR “guillaine barre syndrome” OR “guillain
barre syndrome” OR “guillainbarre syndrome” OR
C10.114.750$ OR GBS OR “demyelinating polyneurop-
athy” OR “demyelinating polyneuropathies” OR
C10.314$ OR C10.668.829.800$ OR “Acute Auto-
immune Neuropathy” OR “acute autoimmune neuropa-
thies” OR “acute inflammatory polyneuropathy” OR
“acute inflammatory polyneuropathies” OR HIV OR
AIDS OR “human immunodeficiency virus” OR
C20.673.480$ OR “multiple sclerosis” OR tumor OR
tumour OR cancer OR malignancy OR carcinoma OR
tumors OR tumours OR cancers OR malignancies OR
carcinomas OR C04$ OR neuralgia OR neuralgias OR
“phantom limb pain” OR “complex regional pain syn-
drome” OR “complex regional pain syndromes” OR
CRPS OR causalgia OR causalgias OR C10.177.195$
OR “spinal cord injury” OR “spinal cord injuries” OR
C26.819$ OR C10.900.850$ OR stroke OR strokes OR
C10.228.140.300.775$ OR paralysis OR C23.888.592.636$
OR “reflex sympathetic dystrophy” OR “reflex sympathetic
dystrophies”)) OR (paresthesia OR paraesthesia OR pares-
thesias OR paraesthesias OR C10.597.751.791.875 OR
“neuropathic pain” OR “painful neuropathy” OR “neuro-
pathic chronic pain” OR Neuropatías OR Neuropatias OR
Polineuropatía OR Polineuropatia OR C10.668.829.500$
OR C10.668.829$) OR (“diabetes complication” OR
“diabetes complications” OR “diabetic complication”
OR “diabetic complications” OR “diabetic neuropathy”
OR “diabetic neuropathies” OR “diabetic neuralgia” OR
“diabetic neuralgias” OR PDN OR “diabetic polyneur-
opathy” OR “diabetic polyneuropathies” OR “diabetic
autonomic neuropathy” OR “diabetic autonomic neu-
ropathies” OR “diabetic mononeuropathy” OR “dia-
betic mononeuropathies” OR “diabetic amyotrophy”
OR C19.246.099.937$ OR herpes OR shingles OR zos-
ter OR HSV OR “neuropathic diabetic pain” OR DPN
OR PHN OR “neuropathic cancer pain” OR “neuro-
pathic pain syndrome” OR “neuropathic pain syn-
dromes” OR “neuropathic chemotherapy-induced
pain” OR “neuropathic chemotherapy induced pain”
OR “chemotherapy-induced peripheral neuropathy”
OR “chemotherapy induced peripheral neuropathy”
OR “chemotherapy-induced peripheral neuropathies”
OR “chemotherapy induced peripheral neuropathies”
OR CINP)) AND (anticonvulsant OR anticonvulsants OR
“anti-convulsant” OR “anti-convulsants” OR “anti convul-
sant” OR “anti convulsants” OR D27.505.954.427.080 OR
“antiepileptic drug” OR “antiepileptic drugs” OR “anti-epi-
leptic drug” OR “anti-epileptic drugs” OR “anti epileptic
drug” OR “anti epileptic drugs” OR “antiseizure drug” OR
“antiseizure drugs” OR “anti-seizure drug” OR “anti-seiz-
ure drugs” OR “anti seizure drug” OR “anti seizure drugs”
OR “antiseizure agent” OR “antiseizure agents” OR “anti-
seizure agent” OR “anti-seizure agents” OR “anti seizure
agent” OR “anti seizure agents” OR “antiepileptic agent”
OR “antiepileptic agents” OR “anti-epileptic agent” OR
“anti-epileptic agents” OR “anti epileptic agent” OR “anti
epileptic agents” OR gabapentin OR Neurontin OR
D27.505.519.625.240$ OR mh:”Neuralgia/therapy” OR
mh:”Neuralgia/ uso terapéutico”)
Searching trial registries
We will conduct a basic search of ClinicaTrials.gov using
the terms below. We will conduct a standard search of
the ICTRP Search Portal using the same terms, and we
will remove the records from ClinicaTrials.gov from
these results before screening.
“945 OR Aclonium OR Alpentin OR Anabix OR
Aneptir OR Apentin OR Apo-Gab OR Bapex OR Blugat
OR Calmpent OR Compulxine OR Dineurin OR Epiven
OR Epleptin OR Equipax OR Gabacalma OR Gabacross
OR Gabadoz OR Gabagamma OR Gabahexal OR Gaba-
lept OR GabaLich OR Gabalix OR Gabamed OR Gaba-
merck OR Gabamox OR Gabaneurin OR Gabanicht OR
Gabanox OR Gabantine OR Gabantin OR Gabapentin
OR Gabaran OR Gabaratio OR Gabarex OR Gabarone
OR Gabaseis OR Gabatal OR Gabatem OR Gabateva OR
Gabatifin OR Gabatine OR Gabatin OR Gabator OR
Gabatur OR Gabax OR Gabenta OR Gabental OR
Gabexal OR Gabex OR Gabexine OR Gabictal OR Gabin
OR Gabix OR Gabmylan OR Gabrion OR Gabtin OR
Gabture OR Galepsi OR Ganin OR Gantin OR Gapenten
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OR Gapridol OR Geabatan OR Gordius OR Gralise OR
Grimodin OR Mengaptrix OR Molnarux OR Nepatic OR
Neruda OR Neugabin OR Neuran OR Neurexal OR
Neuril OR Neuroba OR Neurontin OR Neuros OR Neu-
rostil OR Nopatic OR Normatol OR Nupentin OR Nura-
bax OR Oxaquin OR Pendine OR Pentagab OR Pentin
OR Peronten OR Progresse OR Reinin OR Ritmenal OR
Semerial OR Seni-Ven OR Sipentin OR Sympleptic OR
Tebantin OR Therapentin OR Tremepen OR Vultin OR
Yalipent”
Appendix 2
Quetiapine for bipolar depression searches
Searching for published literature
Databases will be searched using the following terms.
Medline (OVID)
1. Randomized Controlled Trial.pt.
2. Controlled Clinical Trial.pt.






9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Bipolar Disorder/ or Mood Disorders/
13. (Bipolar or “bi polar”).tw.
14. ((rapid or ultradian) adj5 cycl*).tw.
15. (cyclothymic* or hypomani* or mania* or manic*
or mixed episode* or RCBD).tw.
16. ((affective* or mood) adj (disorder* or disturbance*
or dysfunction* or illness* or swing*)).tw.
17. 12 or 13 or 14 or 15 or 16
18. exp Dibenzothiazepines/
19. (quetiapine or Seroquel or “ICI 204636” or “ICI
204646” or ICI204636 or ICI204646 or Socalm or
Tienapine or Alzen or Asicot or Bonogren or
Cedrina or Cizyapine or Derin or Equepin or Equeta
or Etiagen or Etipin or Geldoren or Generiapin or
Gentiapin or Gofyl or Gyrex or Hedonin or Ilufren
or Kefrenex or Ketidose or Ketilept or Ketinel or
Ketipinor or Ketiron or Ketrel or Ketya or Kventiax
or Kwetaplex or Kwetinor or Lantiapin or Lobarr or
Loplive or Loquen or Mylaquel or Nantarid or
Neurorace or Neutapin or Notiabolfen or Pinapaz or
Poetra or Psicotric or QiWei or Qudix or Quelan or
Quelor or Quemed or Quemyl or Quentapil or
Quentiax or Quepin or Quepita or Quepsan or
Questax or Quetapel or Quetastad or Queteper or
Quetex or Quetiafair or Quetialan or Quetiamylan or
Quetiazic or Quetifi or Quetilis or Quetin or
Quetiratio or Quetiron or Quetiser or Quetkare or
Quetrop or Qurax or Qutipin or Q-win or Raikar or
Resirentin or Rocoz or Seotiapim or Sequa or
Sequase or Seratio or Seresano or Serex or Seronia or
Seropia or Seroquin or Setinin or “Shu Si” or Sondate
or Stadaquel or Symquel or Syquet or Taiqutabs or
Tevaquel or Tiaquin or “Tim ASF” or Viketo or





#1 “randomized controlled trial”/exp
#2 “randomization”/exp
#3 “double blind procedure”/exp
#4 “single blind procedure”/exp
#5 random*:ab,ti
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 “animal”/exp OR “animal experiment”/exp
#8 “human”/exp
#9 #7 AND #8
#10 #7 NOT #9
#11 #6 NOT #10
#12 “clinical trial”/exp
#13 (clin* NEAR/3 trial*):ab,ti








#21 “latin square design”/exp
#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR
#18 OR #19 OR #20 OR #21
#23 #22 NOT #10




#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti
#29 #25 OR #26 OR #27 OR #28
#30 #29 NOT #10
#31 #30 NOT (#11 OR #23)
#32 #11 OR #24 OR #31
#33 “bipolar disorder”/exp OR “mania”/de OR “mood
disorder”/de
#34 bipolar:ab,ti OR “bi polar”:ab,ti OR hypoma-
ni*:ab,ti OR mania*:ab,ti OR manic*:ab,ti OR rcbd:ab,ti
OR cyclophren*:ab,ti OR cyclothymi*:ab,ti OR “manio-
depressive”:ab,ti OR “mano depressive”:ab,ti OR (mixed
NEAR/1 episode*):ab,ti
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#35 ((rapid OR ultradian) NEAR/5 cycl*):ab,ti
#36 ((affective* OR mood) NEAR/1 (disorder* OR dis-
turbance* OR dysfunction* OR illness* OR swing*)):ab,ti
#37 #33 OR #34 OR #35 OR #36
#38 “quetiapine”/exp OR “dibenzothiazepine deriva-
tive”/exp
#39 quetiapine:tn,ab,ti OR seroquel:tn,ab,ti OR “ici
204,636”:tn,ab,ti OR “ici 204636”:tn,ab,ti OR “ici
204646”:tn,ab,ti OR ici204636:tn,ab,ti OR ici204646:t-
n,ab,ti OR socalm:tn,ab,ti OR tienapine:tn,ab,ti OR
alzen:tn,ab,ti OR asicot:tn,ab,ti OR bonogren:tn,ab,ti
OR cedrina:tn,ab,ti OR cizyapine:tn,ab,ti OR derin:t-
n,ab,ti OR equepin:tn,ab,ti OR equeta:tn,ab,ti OR etia-
gen:tn,ab,ti OR etipin:tn,ab,ti OR geldoren:tn,ab,ti OR
generiapin:tn,ab,ti OR gentiapin:tn,ab,ti OR gofyl:t-
n,ab,ti OR gyrex:tn,ab,ti OR hedonin:tn,ab,ti OR ilu-
fren:tn,ab,ti OR kefrenex:tn,ab,ti OR ketidose:tn,ab,ti
OR ketilept:tn,ab,ti OR ketinel:tn,ab,ti OR ketipinor:t-
n,ab,ti OR ketiron:tn,ab,ti OR ketrel:tn,ab,ti OR ketya:t-
n,ab,ti OR kventiax:tn,ab,ti OR kwetaplex:tn,ab,ti OR
kwetinor:tn,ab,ti OR lantiapin:tn,ab,ti OR lobarr:tn,ab,ti
OR loplive:tn,ab,ti OR loquen:tn,ab,ti OR mylaquel:t-
n,ab,ti OR nantarid:tn,ab,ti OR neurorace:tn,ab,ti OR
neutapin:tn,ab,ti OR notiabolfen:tn,ab,ti OR pinapaz:t-
n,ab,ti OR poetra:tn,ab,ti OR psicotric:tn,ab,ti OR
qiwei:tn,ab,ti OR qudix:tn,ab,ti OR quelan:tn,ab,ti OR
quelor:tn,ab,ti OR quemed:tn,ab,ti OR quemyl:tn,ab,ti
OR quentapil:tn,ab,ti OR quentiax:tn,ab,ti OR quepin:t-
n,ab,ti OR quepita:tn,ab,ti OR quepsan:tn,ab,ti OR
questax:tn,ab,ti OR quetapel:tn,ab,ti OR quetastad:t-
n,ab,ti OR queteper:tn,ab,ti OR quetex:tn,ab,ti OR quetia-
fair:tn,ab,ti OR quetialan:tn,ab,ti OR quetiamylan:tn,ab,ti
OR quetiazic:tn,ab,ti OR quetifi:tn,ab,ti OR quetilis:tn,ab,ti
OR quetin:tn,ab,ti OR quetiratio:tn,ab,ti OR quetiron:t-
n,ab,ti OR quetiser:tn,ab,ti OR quetkare:tn,ab,ti OR que-
trop:tn,ab,ti OR qurax:tn,ab,ti OR qutipin:tn,ab,ti OR “q
win”:tn,ab,ti OR raikar:tn,ab,ti OR resirentin:tn,ab,ti OR
rocoz:tn,ab,ti OR seotiapim:tn,ab,ti OR sequa:tn,ab,ti OR
sequase:tn,ab,ti OR seratio:tn,ab,ti OR seresano:tn,ab,ti
OR serex:tn,ab,ti OR seronia:tn,ab,ti OR seropia:tn,ab,ti
OR seroquin:tn,ab,ti OR setinin:tn,ab,ti OR “shu si”:tn,ab,ti
OR sondate:tn,ab,ti OR stadaquel:tn,ab,ti OR symquel:t-
n,ab,ti OR syquet:tn,ab,ti OR taiqutabs:tn,ab,ti OR teva-
quel:tn,ab,ti OR tiaquin:tn,ab,ti OR “tim asf”:tn,ab,ti OR
viketo:tn,ab,ti OR vorta:tn,ab,ti OR xeroquel:tn,ab,ti OR
norquetiapine:tn,ab,ti
#40 #38 OR #39
#41 #37 AND #40
#42 #32 AND #41
Central
#1 MeSH descriptor: [Bipolar Disorder] explode all trees
#2 MeSH descriptor: [Mood Disorders] explode all trees
#3 (Bipolar or “bi polar”)
#4 ((rapid or ultradian) near/5 cycl*)
#5 (cyclothymic* or hypomani* or mania* or manic* or
mixed episode* or RCBD)
#6 ((affective* or mood) near/1 (disorder* or disturbance*
or dysfunction* or illness* or swing*))
#7 [#1-#6]
#8 MeSH descriptor: [Dibenzothiazepines] explode all
trees
#9 (quetiapine or Seroquel or “ICI 204636” or “ICI
204646” or ICI204636 or ICI204646 or Socalm or Tiena-
pine or Alzen or Asicot or Bonogren or Cedrina or
Cizyapine or Derin or Equepin or Equeta or Etiagen or
Etipin or Geldoren or Generiapin or Gentiapin or Gofyl
or Gyrex or Hedonin or Ilufren or Kefrenex or Ketidose
or Ketilept or Ketinel or Ketipinor or Ketiron or Ketrel
or Ketya or Kventiax or Kwetaplex or Kwetinor or Lan-
tiapin or Lobarr or Loplive or Loquen or Mylaquel or
Nantarid or Neurorace or Neutapin or Notiabolfen or
Pinapaz or Poetra or Psicotric or QiWei or Qudix or
Quelan or Quelor or Quemed or Quemyl or Quentapil
or Quentiax or Quepin or Quepita or Quepsan or Questax
or Quetapel or Quetastad or Queteper or Quetex or Que-
tiafair or Quetialan or Quetiamylan or Quetiazic or Que-
tifi or Quetilis or Quetin or Quetiratio or Quetiron or
Quetiser or Quetkare or Quetrop or Qurax or Qutipin or
Q-win or Raikar or Resirentin or Rocoz or Seotiapim or
Sequa or Sequase or Seratio or Seresano or Serex or Sero-
nia or Seropia or Seroquin or Setinin or “Shu Si” or Son-
date or Stadaquel or Symquel or Syquet or Taiqutabs or
Tevaquel or Tiaquin or “Tim ASF” or Viketo or Vorta or
Xeroquel or norquetiapine)
#10 #8 or #9
#11 #7 and #10
PsycINFO (Ebsco)
#1 DE “Affective Disorders” OR DE “Bipolar Disorder”
OR DE “Cyclothymic Personality” OR DE “Mania” OR
DE “Hypomania”
#2 TI (Bipolar OR “bi polar” OR hypomani* OR mania*
OR manic* OR mixed episode* OR RCBD OR Cycloph-
ren* OR cyclothymi* OR mixed depression* OR “manio-
depressive” OR “mano depressive”) OR AB (Bipolar OR
“bi polar” OR hypomani* OR mania* OR manic* OR
mixed episode* OR RCBD OR Cyclophren* OR
cyclothymi* OR mixed depression* OR “maniodepressive”
OR “mano depressive”) OR TM (Bipolar OR “bi polar” OR
hypomani* OR mania* OR manic* OR mixed episode* OR
RCBD OR Cyclophren* OR cyclothymi* OR mixed de-
pression* OR “maniodepressive” OR “mano depressive”)
#3 TI ((rapid OR ultradian) N5 cycl*) OR AB ((rapid
OR ultradian) N5 cycl*) OR TM ((rapid OR ultradian)
AND cycl*)
#4 TI ((affective* OR mood) N1 (disorder* OR disturb-
ance* OR dysfunction* OR illness* OR swing*)) OR AB
((affective* OR mood) N1 (disorder* OR disturbance*
OR dysfunction* OR illness* OR swing*)) OR TM
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((affective* OR mood) N1 (disorder* OR disturbance*
OR dysfunction* OR illness* OR swing*))
#5 S1 OR S2 OR S3 OR S4
#6 DE “Quetiapine”
#7 TX (quetiapine OR Seroquel OR “ICI 204636” OR
“ICI 204646” OR ICI204636 OR ICI204646 OR Socalm
OR Tienapine OR Alzen OR Asicot OR Bonogren OR
Cedrina OR Cizyapine OR Derin OR Equepin OR
Equeta OR Etiagen OR Etipin OR Geldoren OR Gener-
iapin OR Gentiapin OR Gofyl OR Gyrex OR Hedonin
OR Ilufren OR Kefrenex OR Ketidose OR Ketilept OR
Ketinel OR Ketipinor OR Ketiron OR Ketrel OR Ketya
OR Kventiax OR Kwetaplex OR Kwetinor OR Lantiapin
OR Lobarr OR Loplive OR Loquen OR Mylaquel OR
Nantarid OR Neurorace OR Neutapin OR Notiabolfen
OR Pinapaz OR Poetra OR Psicotric OR QiWei OR
Qudix OR Quelan OR Quelor OR Quemed OR Quemyl
OR Quentapil OR Quentiax OR Quepin OR Quepita
OR Quepsan OR Questax OR Quetapel OR Quetastad
OR Queteper OR Quetex OR Quetiafair OR Quetialan
OR Quetiamylan OR Quetiazic OR Quetifi OR Quetilis
OR Quetin OR Quetiratio OR Quetiron OR Quetiser
OR Quetkare OR Quetrop OR Qurax OR Qutipin OR
Q-win OR Raikar OR Resirentin OR Rocoz OR Seotia-
pim OR Sequa OR Sequase OR Seratio OR Seresano OR
Serex OR Seronia OR Seropia OR Seroquin OR Setinin
OR “Shu Si” OR Sondate OR Stadaquel OR Symquel OR
Syquet OR Taiqutabs OR Tevaquel OR Tiaquin OR
“Tim ASF” OR Viketo OR Vorta OR Xeroquel OR
norquetiapine)
#8 S6 OR S7
#9 S5 AND S8
CINAHL (Ebsco)
#1 (MH “Bipolar Disorder+“) OR (MH “Affective Dis-
orders”) OR (MH “Affective Disorders, Psychotic”)
#2 TI (Bipolar OR “bi polar” OR hypomani* OR
mania* OR manic* OR mixed episode* OR RCBD OR
Cyclophren* OR cyclothymi* OR mixed depression* OR
“maniodepressive” OR “mano depressive”) OR AB (Bipo-
lar OR “bi polar” OR hypomani* OR mania* OR manic*
OR mixed episode* OR RCBD OR Cyclophren* OR
cyclothymi* OR mixed depression* OR “maniodepres-
sive” OR “mano depressive”)
#3 TI ((rapid OR ultradian) N5 cycl*) OR AB ((rapid
OR ultradian) N5 cycl*)
#4 TI ((affective* OR mood) N1 (disorder* OR disturb-
ance* OR dysfunction* OR illness* OR swing*)) OR AB
((affective* OR mood) N1 (disorder* OR disturbance*
OR dysfunction* OR illness* OR swing*))
#5 S1 OR S2 OR S3 OR S4
#6 (MH “Quetiapine”)
#7 TX (quetiapine OR Seroquel OR “ICI 204636” OR
“ICI 204646” OR ICI204636 OR ICI204646 OR Socalm
OR Tienapine OR Alzen OR Asicot OR Bonogren OR
Cedrina OR Cizyapine OR Derin OR Equepin OR
Equeta OR Etiagen OR Etipin OR Geldoren OR Gener-
iapin OR Gentiapin OR Gofyl OR Gyrex OR Hedonin
OR Ilufren OR Kefrenex OR Ketidose OR Ketilept OR
Ketinel OR Ketipinor OR Ketiron OR Ketrel OR Ketya
OR Kventiax OR Kwetaplex OR Kwetinor OR Lantiapin
OR Lobarr OR Loplive OR Loquen OR Mylaquel OR
Nantarid OR Neurorace OR Neutapin OR Notiabolfen
OR Pinapaz OR Poetra OR Psicotric OR QiWei OR
Qudix OR Quelan OR Quelor OR Quemed OR Quemyl
OR Quentapil OR Quentiax OR Quepin OR Quepita
OR Quepsan OR Questax OR Quetapel OR Quetastad
OR Queteper OR Quetex OR Quetiafair OR Quetialan
OR Quetiamylan OR Quetiazic OR Quetifi OR Quetilis
OR Quetin OR Quetiratio OR Quetiron OR Quetiser
OR Quetkare OR Quetrop OR Qurax OR Qutipin OR
Q-win OR Raikar OR Resirentin OR Rocoz OR Seotia-
pim OR Sequa OR Sequase OR Seratio OR Seresano OR
Serex OR Seronia OR Seropia OR Seroquin OR Setinin
OR “Shu Si” OR Sondate OR Stadaquel OR Symquel OR
Syquet OR Taiqutabs OR Tevaquel OR Tiaquin OR
“Tim ASF” OR Viketo OR Vorta OR Xeroquel OR
norquetiapine)
#8 S6 OR S7
#9 S5 AND S8
PubMed
1. ((randomized controlled trial[pt]) OR (controlled
clinical trial[pt]) OR (randomised[tiab] OR
randomized[tiab]) OR (placebo[tiab]) OR (drug
therapy[sh]) OR (randomly[tiab]) OR (trial[tiab])
OR (groups[tiab])) NOT (animals[mh] NOT
humans[mh])
2. (Bipolar[tw] OR “bi polar”[tw]) NOT Medline[sb]
3. ((rapid[tw] OR ultradian[tw]) AND cycl*[tw]) NOT
Medline[sb]
4. (hypomani*[tw] OR mania*[tw] OR manic*[tw]
OR mixed episode*[tw] OR RCBD[tw] OR
Cyclophren*[tw] OR cyclothymi*[tw] OR mixed
depression*[tw] OR “maniodepressive”[tw] OR
“mano depressive”[tw]) NOT Medline[sb]
5. ((affective*[tw] OR mood[tw]) AND (disorder*[tw]
OR disturbance*[tw] OR dysfunction*[tw] OR
illness*[tw] OR swing*[tw])) NOT Medline[sb]
6. #2 OR #3 OR #4 OR #5
7. quetiapine[tw] OR Seroquel[tw] OR “ICI 204636”
OR “ICI 204646”[tw] OR ICI204636[tw] OR
ICI204646[tw] OR Socalm[tw] OR Tienapine[tw]
OR Alzen[tw] OR Asicot[tw] OR Bonogren[tw] OR
Cedrina[tw] OR Cizyapine[tw] OR Derin[tw] OR
Equepin[tw] OR Equeta[tw] OR Etiagen[tw] OR
Etipin[tw] OR Geldoren[tw] OR Generiapin[tw] OR
Gentiapin[tw] OR Gofyl[tw] OR Gyrex[tw] OR
Hedonin[tw] OR Ilufren[tw] OR Kefrenex[tw] OR
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Ketidose[tw] OR Ketilept[tw] OR Ketinel[tw] OR
Ketipinor[tw] OR Ketiron[tw] OR Ketrel[tw] OR
Ketya[tw] OR Kventiax[tw] OR Kwetaplex[tw] OR
Kwetinor[tw] OR Lantiapin[tw] OR Lobarr[tw] OR
Loplive[tw] OR Loquen[tw] OR Mylaquel OR
Nantarid[tw] OR Neurorace[tw] OR Neutapin[tw]
OR Notiabolfen[tw] OR Pinapaz[tw] OR Poetra[tw]
OR Psicotric[tw] OR QiWei[tw] OR Qudix[tw] OR
Quelan[tw] OR Quelor[tw] OR Quemed[tw] OR
Quemyl[tw] OR Quentapil[tw] OR Quentiax[tw]
OR Quepin[tw] OR Quepita OR Quepsan[tw] OR
Questax[tw] OR Quetapel[tw] OR Quetastad[tw]
OR Queteper[tw] OR Quetex[tw] OR Quetiafair[tw]
OR Quetialan[tw] OR Quetiamylan[tw] OR
Quetiazic[tw] OR Quetifi[tw] OR Quetilis[tw] OR
Quetin[tw] OR Quetiratio[tw] OR Quetiron[tw] OR
Quetiser[tw] OR Quetkare[tw] OR Quetrop[tw] OR
Qurax[tw] OR Qutipin[tw] OR Q-win[tw] OR Rai-
kar[tw] OR Resirentin[tw] OR Rocoz[tw] OR Seo-
tiapim[tw] OR Sequa[tw] OR Sequase[tw] OR
Seratio[tw] OR Seresano[tw] OR Serex[tw] OR Ser-
onia[tw] OR Seropia[tw] OR Seroquin[tw] OR Seti-
nin[tw] OR “Shu Si”[tw] OR Sondate[tw] OR
Stadaquel[tw] OR Symquel[tw] OR Syquet[tw] OR
Taiqutabs[tw] OR Tevaquel[tw] OR Tiaquin[tw] OR
“Tim ASF”[tw] OR Viketo[tw] OR Vorta[tw] OR
Xeroquel[tw] OR norquetiapine[tw]
8. #6 AND #7
9. #1 AND #8
Searching trial registries
We will conduct a basic search of ClinicaTrials.gov using
the terms below. We will conduct a standard search of
the ICTRP Search Portal using the same terms, and we
will remove the records from ClinicaTrials.gov from
these results before screening.
“Dibenzothiazepines OR quetiapine OR Seroquel OR
“ICI 204636” OR “ICI 204646” OR ICI204636 OR
ICI204646 OR Socalm OR Tienapine OR Alzen OR Asi-
cot OR Bonogren OR Cedrina OR Cizyapine OR Derin
OR Equepin OR Equeta OR Etiagen OR Etipin OR Gel-
doren OR Generiapin OR Gentiapin OR Gofyl OR Gyrex
OR Hedonin OR Ilufren OR Kefrenex OR Ketidose OR
Ketilept OR Ketinel OR Ketipinor OR Ketiron OR Ketrel
OR Ketya OR Kventiax OR Kwetaplex OR Kwetinor OR
Lantiapin OR Lobarr OR Loplive OR Loquen OR Myla-
quel OR Nantarid OR Neurorace OR Neutapin OR
Notiabolfen OR Pinapaz OR Poetra OR Psicotric OR
QiWei OR Qudix OR Quelan OR Quelor OR Quemed
OR Quemyl OR Quentapil OR Quentiax OR Quepin OR
Quepita OR Quepsan OR Questax OR Quetapel OR
Quetastad OR Queteper OR Quetex OR Quetiafair OR
Quetialan OR Quetiamylan OR Quetiazic OR Quetifi
OR Quetilis OR Quetin OR Quetiratio OR Quetiron OR
Quetiser OR Quetkare OR Quetrop OR Qurax OR Quti-
pin OR Q-win OR Raikar OR Resirentin OR Rocoz OR
Seotiapim OR Sequa OR Sequase OR Seratio OR Sere-
sano OR Serex OR Seronia OR Seropia OR Seroquin
OR Setinin OR “Shu Si” OR Sondate OR Stadaquel OR
Symquel OR Syquet OR Taiqutabs OR Tevaquel OR Tia-
quin OR “Tim ASF” OR Viketo OR Vorta OR Xeroquel
OR norquetiapine”
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